

Multi-Panel Urine Test Cup Cataloque No. See Box label

The Prime Screen[®] Multi-Panel Urine Test Cup is competitive binding, lateral flow immunochromatographic assays for qualitative and simultaneous detection of Amphetamine, Secobarbital, Buprenorphine, Oxazepan Cocaine, Cotinine, 2-ethylidene-1,5-dimethyl-3,3-diphenylpyrrolidine (EDDP), Ethyl Glucuronide, Fentanyl, vnthetic Cannabinoids, Ketamine, Kratom, Methylenedioxymethamphetamine, Methamphetamine, Morphin lethadone. Opiate. Oxycodone. Phencyclidine. Propoxyphene. Nortriptyline. Cannabinoids. Tramadol and Alcohol in human urine with below cutoff concentrations and approximate detection time:

Drug (Identifier)	Calibrator	Cut-off Level	Minimum Detection Time	Maximum Detection Time
Amphetamine (AMP300)	d-Amphetamine	300 ng/mL	2-7 hours	1-2 days
Amphetamine (AMP500)	d-Amphetamine	500 ng/mL	2-7 hours	1-2 days
Amphetamine (AMP1000)	d-Amphetamine	1000 ng/mL	2-7 hours	1-2 days
Secobarbital (BAR)	Secobarbital	300 ng/mL	2-4 hours	1-4 days
Buprenorphine (BUP)	Buprenorphine	10 ng/mL	4 hours	1-3 days
Oxazepam (BZO200)	Oxazepam	200 ng/mL	2-7 hours	1-2 days
Oxazepam (BZO300)	Oxazepam	300 ng/mL	2-7 hours	1-2 days
Cocaine (COC100)	Benzoylecgonine	100 ng/mL	1-4 hours	2-4 days
Cocaine (COC150)	Benzoylecgonine	150 ng/mL	1-4 hours	2-4 days
Cocaine (COC300)	Benzoylecgonine	300 ng/mL	1-4 hours	2-4 days
Cotinine (COT)	Cotinine	200 ng/mL	2-8 hours	1-7 days
EDDP100	2-ethylidene-1,5- dimethyl-3,3- diphenylpyrrolidine	100 ng/mL	3-8 hours	1-3 days
EDDP300	2-ethylidene-1,5- dimethyl-3,3- diphenylpyrrolidine	300 ng/mL	3-8 hours	1-3 days
Ethyl Glucuronide (EtG)	Ethyl Glucuronide	500 ng/mL	1-2 hours	Up to 3+ days
Fentanyl (FTY20)	Norfentanyl	20 ng/mL	1-4 hours	1-2days
Fentanyl (FTY100)	Fentanyl	100 ng/mL	1-4 hours	1-2days
Synthetic Cannabinoid (K2)	JWH-018 Pentanoic Acid JWH-073 Butanoic Acid	50 ng/mL 50 ng/mL	8-12 hours	Up to 5+ days
Ketamine (KET 300)	Ketamine	300 ng/mL	2-4 hours	2-3 days
Ketamine (KET 1000)	Ketamine	1000 ng/mL	2-4 hours	2-3 days
Kratom (KRA)	Mitragynine	300 ng/mL	7 hours	3 days
Methylenedioxymethamp hetamine (MDMA)	3,4- Methylenedioxymethamp hetamine (MDMA)	500 ng/mL	2-7 hours	2-4 days
Methamphetamine (MET300/mAMP300)	D(+)-Methamphetamine	300 ng/mL	2-7 hours	2-4 days
Methamphetamine (MET500/mAMP500)	D(+)-Methamphetamine	500 ng/mL	2-7 hours	2-4 days
Methamphetamine (MET1000/mAMP1000)	D(+)-Methamphetamine	1000 ng/mL	2-7 hours	2-4 days
Morphine (MOP/OPI100)	Morphine	100 ng/mL	2 hours	2-3 days
Morphine (MOP/OPI300)	Morphine	300 ng/mL	2 hours	2-3 days
Methadone (MTD200)	Methadone	200 ng/mL	3-8 hours	1-3 days
Methadone (MTD300)	Methadone	300 ng/mL	3-8 hours	1-3 days
Opiate (OPI)	Morphine	2000 ng/mL	2 hours	2-3 days
Oxycodone (OXY)	Oxycodone	100 ng/mL	4 hours	1-3 days
Phencyclidine (PCP)	Phencyclidine	25 ng/mL	4-6 hours	7-14 days
Propoxyphene (PPX)	Propoxyphene	300 ng/mL	2 hours	2-3 days
Nortriptyline (TCA)	Nortriptyline	1000 ng/mL	8-12 hours	2-7 days
Cannabinoids (THC25)	11-nor-∆9-THC-9-COOH	25 ng/mL	2 hours	Up to 5+ days
Cannabinoids (THC40)	11-nor-∆9-THC-9-COOH	40 ng/mL	2 hours	Up to 5+ days
Cannabinoids (THC50)	11-nor-∆9-THC-9-COOH	50 ng/mL	2 hours	Up to 5+ days
Tramadol (TRA 100)	Tramadol	100 ng/mL	8-12 hours	3-7 days
Tramadol (TRA 200)	Tramadol	200 ng/mL	8-12 hours	3-7 days
Alcohol (ETOH)	Alcohol	0.04 g/dL	-	-

Configurations of the Prime Screen[®] Multi-Panel Urine Test Cup can consist of any combination of the above listed drug analytes. It is intended for forensic use only.

It is not intended to distinguish between prescription use or abuse of these drugs. Clinical consideration and professional judgment should be applied to any drug of abuse test result, particularly in evaluating a preliminary positive result

The tests provide only preliminary results. To obtain a confirmed analytical result, a more specific alternate chemical method must be used. Chromatography/Mass Spectrometry (GC/MS) or Liquid Chromatography/Tandem Mass Spectrometry (LC/MS-MS) is the recommended confirmatory method.

WARNINGS AND PRECAUTIONS

- 1. The test kit is for external use only.
- 2. Discard after first use. The test kit cannot be used more than once.
- Do not use the test kit beyond expiration date.
- 4. Do not use the test kit if the pouch is punctured or not well sealed. 5. Keep out of the reach of children.

CONTENT OF THE KIT

- 1. Prime Screen® test devices, each in one pouch with two desiccants. The desiccants are for storage purposes only and are not used in the test procedure.
- Package Insert
- Adulteration Color Comparison Charts (If equipped)
- Security Seals

MATERIAL REQUIRED BUT NOT PROVIDED

Timer or Clock

STORAGE AND STABILITY

- Store at 4°C-30°C (39°E-86°E) in the sealed nouch up to the expiration date
- Keep away from direct sunlight, moisture and heat.
- DO NOT FREEZE.

SPECIMEN COLLECTION

WHEN TO COLLECT URINE FOR THE TEST?

Collect urine specimen after minimum detection time following suspected drug use. Urine collection time is very important in detecting any drugs of abuse. Each drug is cleared by the body and is detected in the urine at different times and rates. Please refer to the minimum or maximum detection time of each drug in this instruction

HOW TO COLLECT URINE?

- . Remove the test cup from the foil pouch by tearing at the notch. Use it as soon as possible. Instruct the donor to remove the test cup lid and void directly into the test cup until reach the Minimum Urine Level mark (approximately 25 mL). It is acceptable to collect extra volume of urine. If insufficient specimen has been collected, instruct the donor to provide urine specimen again with another new test cup. Wipe off any splashes or spills that may be on the outside of the cup. It is recommended to wear gloves when handling the test cup with urine specimen.
- . Observe the temperature strip affixed on the test cup between 2 to 4 minutes after urine is voided into the cup. The temperature between 32°C to 38°C (90°F-100°F) indicates the fresh uncontaminated specimen. If the temperature is out of this range, instruct the donor to provide urine specimen again with another new test cup.

TEST PROCEDURE

Test should be performed at room temperature 18°C-30°C (65°F-86°F).

- 1. After the urine has been collected properly, tighten the lid and place the test cup on a flat surface. 2. Peel off the label from right to left.
- 3. For the adulteration strip(s) if equipped, read results immediately, or at 30 seconds, or at 45 seconds and compare each adulterant pad to verify pad color is within acceptable range according to the Adulteration Color Comparison Chart. If the results indicate adulteration, do not read the drug test results. Instruct the donor to provide urine specimen again with another new test cup.
- 4. For the alcohol test, read the alcohol test result at 2 minutes. Do not read results after 2 minutes.
- 5. For the drug tests, read the drug test results at 5 minutes. Do not read results after 5 minutes.



Note: Drug test results after more than 5 minutes may be not accurate and should not be read

READING THE RESULTS

DRUG TEST:

Negative (-)


A colored band is visible in each Control Region (C) and the appropriate Test Region (T). It indicates that the concentration of the corresponding drug of that specific test zone is zero or below the detection limit of the

Preliminary Positive (+)

A colored band is visible in each Control Region (C). No colored band appears in the appropriate Test Region (T). It indicates a preliminary positive result for the corresponding drug of that specific test zone.

Invalid

Region (T), the test is invalid. Another test should be run to re-evaluate the specimen. If the new test still Buprenorphine is as effective as Methadone but demonstrates a lower level of physical dependence. The provides an invalid result, please contact the distributor from whom you purchased the product. When calling, be sure to provide the lot number of the test.



Note: There is no meaning attributed to line color intensity or width.


A preliminary positive test result does not always mean a person took drugs and a negative test result does Cocaine derived from leaves of coca plant, is a potent central nervous system stimulant and a local anesthetic not always mean a person did not take drugs. There could be a number of factors that affect the reliability of Among the psychological effects induced by using cocaine are euphoria, confidence and a sense of increased drua tests.

Almost no color change on test pad in comparison with the provided colored chart. The negative result of the autonomic ganglia and central nervous system when in humans. Nicotine is found in tobacco products indicates that the concentration of ethyl alcohol in urine is less than 0.04 g/dL

Preliminary Positive (+)

in urine is 0.04% or higher.





The test should be considered invalid if only the edge of the reaction pad turned color that might be ascribed to insufficient sampling. Another test should be run to re-evaluate the specimen. If test still fails, please contact the distributor with the lot number

What Is the False Positive Test?

The definition of the false positive test would be an instance where a substance is identified incorrectly by the Prime Screen® Multi-Panel Urine Test Cup. The most common causes of the false positive test are cross reactants. Certain foods and medicines, diet plan drugs and nutritional supplements may cause the false positive test result

What is the False Negative Test?

The definition of the false negative test is that the initial drug is present but isn't detected by the Prime Screen® Multi-Panel Urine Test Cup. If the specimen is diluted, or the specimen is adulterated that may cause false negative result.

If suspect someone is taking drugs but get the negative test results, please test again at another time.

TEST LIMITATIONS

- 1. This test kit has been developed for testing urine specimen only. No other fluids have been evaluated, DO NOT use it to test anything other than urine
- 2. Adulterated urine specimen may produce false results. Strong oxidizing agents such as bleach (hypochlorite) can oxidize drug analytes. If a specimen is suspected of being adulterated, obtain a new
- 3. It is possible that technical or procedural errors, as well as other interfering substances in the urine specimen may cause false results.
- 4. This test is a qualitative screening assay. It is not designed to determine the quantitative concentration of drugs or the level of intoxication.

SUMMARY

Amphetamine (AMP)

Amphetamine and the structurally related "designer" drugs are sympathomimetic amines whose biological effects include potent central nervous system (CNS) stimulation, anorectic, hyperthemic, and cardiovascular properties. They are usually taken orally, intravenously, or by smoking. Amphetamines are readily absorbed from the gastrointestinal tract and are then either deactivated by the liver or excreted unchanged in the urine with a half-life of about 12 hours. It can be detected in the urine for 1 to 2 days after use. Amphetamine is metabolized to deaminated (hippuric and benzoic acids) and hydroxylated metabolites. Methamphetamine is partially metabolized to amphetamine and its major active metabolite. Amphetamines increase the heart rate and blood pressure, and suppress the appetite. Some studies indicate that heavy abuse may result in permanent damage to certain essential nerve structural in the brain.

Secobarbital (BAR)

Barbiturates are a class of central nervous system depressions. They have a wide range of half-life of 2 to 40 hours and can be detected in the urine for 1 to 4 days after use. Phenobarbital is a long acting barbiturate derivative that has been used as a daytime sedative and very extensively as an anticonvulsant. Pentobarbital and secobarbital are two examples of a short acting barbiturate sedative. Abuse of barbiturates can lead not only to impaired motor coordination and mental disorder, but also to respiratory collapse, coma and even death Barbiturates are taken orally, rectally, or by intravenous and intramuscular injections. Short-acting barbiturates will generally be excreted in urine as metabolites, while the long-acting barbiturates will primarily appear

Buprenorphine (BUP)

Buprenorphine is a potent analoesic often used in the treatment of opioid addiction. The drug is sold under the trade names Subutex[™], Buprenex[™], Temgesic[™] and Suboxone[™]; all of which contain Buprenorphine HCI alone or in combination with Naloxone HCI. Therapeutically, Buprenorphine is used as a substitution treatment for opioid addicts. A substitution treatment is a form of medical care offered to opiate addicts (primarily heroin If a colored band is not visible in each of the Control Region (C) or a colored band is only visible in the Test addicts) based on a similar or identical substance to the drug normally used. In substitution therapy, plasma half-life of Buprenorphine is 2-4 hours. While complete elimination of a single-dose of the drug can take as long as 6 days, the detection window for the parent drug in urine is thought to be approximately 3 days.

Oxazenam (BZO)

Benzodiazepines are the most widely used anxiolytic drugs. They are used extensively as anti-anxiety agents, hypnotics, muscle relaxants and anti-convulsants. They are taken orally or sometimes by injection and have a wide range of half-life from 2 to 40 hours. They can generally be detected for 1 to 2 days after Benzodiazepines use. Benzodiazepines are metabolized in the liver. Some Benzodiazepines and their metabolites are excreted in the urine. Their use can result in drowsiness and/or confusion. Benzodiazepines potentiate alcohol and other CNS depressants. Psychological and physical dependence on benzodiazepines can develop if high doses of the drug are given over a prolonged period.

energy, accompanied by increased heart rate, dilation of the pupils, fever, tremors and sweating. Cocaine is excreted in urine primarily as benzovlecgonine in a short period of time.

Cotinine (COT)

Cotinine is an alkaloid found in tobacco and is also a major metabolite of Nicotine, which produces stimulation such as cigarettes, tobacco chew, and nicotine patches or gums. It is an addictive substance and is poisonous in a large amount. In addition to addiction, some of the other substances within tobacco products, such as

carbon monoxide or tar, are dangerous to the body and can lead to medical conditions such as emphysema, A distinct color developed all over the pad. The positive result indicates that the concentration of ethyl alcohol lung cancer, and heart disease. In a 24-hour urine, approximately 5% of a nicotine dose is excreted as Opiate refers to any drug that is derived from the opium poppy, including the natural products, morphine and unchanged drug with 10% as cotinine and 35% as hydroxycotinine: the concentrations of other metabolites are believed to account for less than 5%. While Cotinine is thought to be an inactive metabolite, its elimination profile is more stable than that of Nicotine which is largely urine PH dependent. Cotinine is stable in body fluids and has a relatively long half-life of approximately 17 hours, and is typically detectable for several days (up to one week) after the use of tobacco, therefore the detection of Cotinine is less dependent on the time of sampling than that of Nicotine

> Nicotine and Cotinine are rapidly eliminated by the kidney; the window of detection for cotinine in urine at a cutoff level of 200 ng/mL is expected to be up to 2~3 days after nicotine use.

> intake, even after alcohol is no longer measurable. Traditional laboratory methods detect the actual alcohol in

the body, which reflects current intake within the past few hours (depending on how much was consumed).

The presence of EtG in urine is a definitive indicator that it can be detected in the urine for 3 to 4 days after

recent intake of alcohol than measuring for the presence of alcohol itself. The EtG test can aid in the diagnosis

of drunk driving and alcoholism, which has important significance in the forensic identification and medical

potent than morphine. Fentanyl is a strong agonist at the u-opioid receptors. Historically it has been used to

treat breakthrough pain and is commonly used in pre-procedures as a pain reliever as well as an anesthetic in

combination with a benzodiazepine. Fentanyl is frequently given intrathecally as part of spinal anesthesia or

Synthetic cannabinoids are psychoactive designer drugs derived of natural herbs sprayed with synthetic

chemicals that, when consumed, allegedly mimic the effects of cannabis. It is best known by the brand names

cannabis, such as THC. Although synthetic cannabinoids do not produce positive results in drug tests for

drinking alcohol, even alcohol is eliminated from the body. Therefore, EtG is a more accurate indicator of the

Methadone is a synthetic analgesic drug that is originally used in the treatment of narcotic addicts. The detection of EDDP is more beneficial than traditional methadone screening since EDDP exists only in urine from individuals that ingested methadone. The tampering of specimens by spiking the urine with methadone can be prevented. Secondly, renal clearance of EDDP is not affected by urinary pH, therefore the EDDP test provides a more accurate result of methadone ingestion than the methadone parent screening.

Ethyl Glucuronide (EtG) Ethyl Glucuronide is a direct metabolite of alcohol. Presence in urine may be used to detect recent alcohol

Fentanyl (FTY)

Ketamine (KET)

Ketamine is a sort of medical stupefacient. The principal metabolites are non-ketamine. Smoking, mainlining, snuffing, and dissolving into drink or alcohol are the primary method of use of ketamine. Ketamine is usually administered in combination with heroin, marijuana etc, for the relief of moderate to severe pain. Overdose may cause central nervous system effects, do harm to liver and kidney, and even cause death. Ketamine is netabolized in the liver. Over 70% ketamine metabolites and only 5% original drugs are excreted in the urine. They can generally be detected for 2 to 4 hours after ketamine use.

Kratom (KRA)

Kratom (Mitragyna speciosa) is a plant indigenous to Thailand and Southeast Asia. Kratom leaves produce pain, diarrhea, cough, and opioid withdrawal, Recently, kratom has become widely available in the United well defined and studies are limited, but its safety profile has become a national and international concern, primarily due to excessive consumption being linked to increase in hospital visits for hepatic injury, seizures, coma, and death. The main active ingredients include Mitragynine and 7-Hydroxymitrgynine, which can be

company for the treatment of obesity. Those who take the drug frequently report adverse effects, such as increased muscle tension and sweating. MDMA is not clearly a stimulant, although it has, in common with amphetamine drugs, a capacity to increase blood pressure and heart rate. MDMA does produce some excreted as metabolites. perceptual changes in the form of increased sensitivity to light, difficulty in focusing, and blurred vision in some users. Its mechanism of action is thought to be via release of the neurotransmitter serotonin. MDMA may also release dopamine, although the general opinion is that this is a secondary effect of the drug (Nichols and Oberlender, 1990). The most pervasive effect of MDMA, occurring in virtually all people who took a reasonable

Morphine (MOP/OPI300)

The opiates such as heroin, morphine, and codeine are derived from the resin of opium poppy. The principal found in the urine of a person who has taken only heroin. The body also changes codeine to morphine. Thus, and/or codeine use. The test for Morphine (MOP/OPI300) of the Prime Screen[®] Multi-Panel Urine Test Cup negative result. vields a positive result when the morphine in urine exceeds 300 ng/mL.

Methadone (MTD)

Methadone is a synthetic analgesic drug that is originally used in the treatment of narcotic addicts. Among the psychological effects induced by using methadone are analgesia, sedation and respiratory depression. Overdose of methadone may cause coma or even death. It is administered orally or intravenously and is metabolized in the liver and excreted in urine as methadone, EDDP, EMDA and methadol. The kidneys are a To serve as a procedure control, a colored line will appear at the Control Region (C), where the goat anti mouse major route of methadone excretion. Methadone has a biological half-life of 15 to 60 hours.

Opiate (OPI)

codeine, and the semi-synthetic drugs such as heroin. Opioid is more general, referring to any drug that acts on the opioid receptor. Opioid analgesics comprise a large group of substances which control pain by depressing the central nervous system. Large doses of morphine can produce higher tolerance levels, physiological dependency in users and may lead to substance abuse. Morphine is excreted unmetabolized and is also the major metabolic product of codeine and beroin. Morphine is detectable in the urine for several days after an opiate dose. The test for Morphine 2000 (OPI) of the Prime Screen® Multi-Papel Urine Test Cup vields a positive result when the morphine in urine exceeds 2000 ng/mL.

Oxycodone (OXY)

xycodone is known as Oxycontin and Roxicodone. It is an ingredient of Percodan, Percocet, Roxicet and Tylox. Oxycodone is a semi-synthetic opiates derived from opium. Like other opiates, Oxycodone is characterized by it analoesic properties, and the tendency for users to form a physical dependency and develop tolerance with extended use. Oxycodone is usually administered in combination with non-opiate analgesic such as acetaminophen and salicylates for the relief of moderate to severe pain. Oxycodone is a central nervous system depressant that may cause drowsiness, dizziness, lethargy, weakness and confusion. Toxicity in an overdose of Oxycodone can lead to stupor, coma, muscle flaccidity, severe respiratory depression, hypotension, and cardiac arrest. Oxycodone is metabolized by N- and O-demethylation. One of the metabolites oxymorphone, is a potent narcotic analgesic, while the other, noroxycodone, is relatively inactive. Between 33 to 61% of a single dose of Oxycodone is excreted in a 24 hour urine collection and consists of 13-19% free Oxycodone, 7-29% glucuronide conjugated Oxycodone, 13-14% glucuronide conjugated oxymorphone and an unknown amount of noroxycodone. The detection time window of Oxycodone is 1-3 days following use.

Phencyclidine (PCP)

Phencyclidine is an arylcyclohexylamine that was originally used as an anesthetic agent and a veterinary tranguilizer. Phencyclidine can produce hallucinations, lethargy, disorientation, loss of coordination, trance-like ecstatic states, a sense of euphoria and visual distortions. It has many street names, such as "angel dust" and "crystal cyclone," etc. phencyclidine can be administered orally, by nasal ingestion, smoking, or by intravenous injection. It is metabolized in the liver and excreted through the kidneys in urine in unchanged form and oxidized Fentanyl is a potent, synthetic narcotic analgesic with a rapid onset and short duration of action. It was first metabolites with a half-life of about 12 hours. Suction and urinary acidification in the treatment of overdose synthesized by Janssen Pharmaceutica (Belgium) in the late 1950s, and It is approximately 100 times more typically reduces its half-life from three days to one day.

Propoxyphene (PPX)

Propoxyphene, a synthetic opiate agonist, is structurally similar to methadone. Propoxyphene is a narcotic analgesic used to relieve mild to moderate pain. The principal metabolites are nordextropropoxyphene. The combination usage of propoxyphene, aspirin, acetaminophen or other sedatives can lead cooperative interaction. Abuse of propoxyphene can lead nausea, vomit, astriction, illusion, hallucination, heart poisoning, lung dropsy and even death. Proposyphene is metabolized in the liver and excreted in urine as nordextropropoxyphene. Thus the presence of the propoxyphene or its metabolites in the urine indicates K2 and Spice. Synthetic cannabinoids act on the body in a similar way to cannabinoids naturally found in proposyphene use.

Nortriptyline (TCA)

TCA (Tricvclic Antidepressants) are commonly used for the treatment of depressive disorders. TCA overdoses can result in profound central nervous system depression, cardiotoxicity and anticholinergic effects. TCA overdose is the most common cause of death from prescription drugs. TCAs are taken orally or sometimes by injection. TCAs are metabolized in the liver. Both TCAs and their metabolites are excreted in urine mostly in the form of metabolites for up to ten days.

Cannabinoids (THC)

Cannabinoids are hallucinogenic agents derived from the flowering portion of the hemp plant. The active ingredients in Cannabinoids, THC & Cannabinol can be metabolized and excreted as 11-nor-Q9tetrahydrocannabinol-9-carboxylic acid with a half-life of 24 hours. They can be detected for 1 to 5 days after use. Smoking is the primary method of use of Cannabinoids/cannabis. Higher doses used by abusers produce complex stimulant and opioid-like analaesic effects. In Asia, it is often used to stave off fatigue and to manage central nervous system effects, altered mood and sensory perceptions, loss of coordination, impaired shortterm memory, anxiety, paranoia, depression, confusion, hallucinations and increased heart rate. A tolerance to States and Europe by means of smoke shops and the Internet. The clinical manifestations of kratom are not the cardiac and psychotropic effects can occur, and withdrawal syndrome produces restlessness, insomnia, anorexia and nausea.

Tramadol (TRA)

Tramadol [2-(dimethylaminomethyl)-1-(3-methoxyphenyl) cyclohexanol] is used similarly to codeine, to treat moderate to moderately severe pain. It is a synthetic analog of the phenanthrene alkaloid codeine and, as such, is an opioid and also a prodrug (codeine is metabolized to morphine, tramadol is converted to Odesmethyltramadol). Tramadol and its metabolites are excreted primarily in the urine with observed plasma half-lives of 6.3 and 7.4 hours for tramadol and O-desmethyltramadol (denoted M1), respectively. Approximately 30% of the dose is excreted in the urine as unchanged drug, whereas 60% of the dose is

Alcohol (ETOH)

Alcohol Test is intended for use to detect the presence of alcohol in urine greater than 0.04%. Alcohol intoxication can lead to loss of alertness, coma, death and as well as birth defects. The BAC at which a person becomes impaired is variable. The United States Department of Transportation (DOT) has established a BAC of 0.02% (0.02 g/dL) as the cut-off level at which an individual is considered positive for the presence of alcohol. Since the urine alcohol concentration is normally higher than that in saliva and blood, the cutoff concentration Methamphetamine is a potent sympathomimetic agent with therapeutic applications. Acute higher doses lead for alcohol in urine was set at 0.04%. Normally, it will take at least 30 minutes for the alcohol to be detected in

PRINCIPI I

The Prime Screen[®] Multi-Panel Urine Test Cup is a competitive immunoassay that is used to screen for the presence of drugs of abuse in urine. It is a chromatographic absorbent device in which drugs in a sample competitively combine to a limited number of drug monoclonal antibody (mouse) conjugate binding sites.

When the absorbent end is immersed into urine specimen, the urine is absorbed into the device by capillary metabolites of opiates are morphine, morphine-3-glucuronide normorphine and codeine with a half-life of about action, mixes with the respective drug monoclonal antibody conjugate, and flows across the pre-coated 3 hours. Heroin is aujckly metabolized to morphine. Thus, morphine and morphine alucuronide might both be membrane. When sample drug levels are zero or below the target cutoff (the detection sensitivity of the test). respective drug monoclonal antibody conjugate binds to the respective drug-protein conjugate immobilized in the presence of morphine (or the metabolite, morphine glucuronide) in the urine indicates heroin, morphine the Test Region (T) of the device. This produces a colored Test line that, regardless of its intensity, indicates a

> When sample drug levels are at or above the target cutoff, the free drug in the sample binds to the respective drug monoclonal antibody conjugate preventing the respective drug monoclonal antibody conjugate from binding to the respective drug-protein conjugate immobilized in the Test Region (T) of the device. This prevents the development of a distinct colored band in the test region, indicating a potentially positive result.

IgG polyclonal antibody immobilized in, if the test has been performed properly.

<form>NumberNumbe</form>	-												<u> </u>		-												
<form>Note in a part of a</form>	Q	UALIT	Y CON	FROL									0	0	2	20	20	100% (84.5% -100%)			+	0	0	2	21	19	100% (91.2% - 100%) 95% (83.5% - 98.6%)
III	U	sers sh	nould fol	llow the appro	opriate fed	eral, state, an	d local guideline	es concerning	g the frequency of assaying									· · · · · · · · · · · · · · · · · · ·	MET		+				-	-	100% (91.2% - 100%)
<form><<<<<<<<<<<<<<<<<<</form>	e	xternal	quality	control materi	ials. Even	though there i	is an internal pro	ocedural cont	trol line in the test device in									· · · · · · · · · · · · · · · · · · ·			-	10	15			-	95% (83.5% - 98.6%)
<form>Numerical and a base of a base</form>										сос	Vie	wer +	0	0	2	27	13	100% (91.2% -100%))	Viewer	+	0	0	2	20	20	100% (91.2% - 100%)
<form></form>										(100)	A	-	10	15	13	0	0	95% (83.5% - 98.6%)	(500)	В	-	10	15	13	0	0	95% (83.5% - 98.6%)
		-				· ·	-									27		100% (91.2% - 100%)			+		•			20	100% (91.2% - 100%)
									In cach new lot, cach new								-	· · · · · · · · · · · · · · · · · · ·		С	-				-	-	95% (83.5% - 98.6%)
		1		1 - C														· · · · · · · · · · · · · · · · · · ·			+		-				100% (84.5% - 100%)
No. No. <td>P</td> <td>ERFO</td> <td>RMANC</td> <td>E CHARACT</td> <td>ERISTICS</td> <td></td> <td></td> <td></td> <td></td> <td>000</td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td> <td>· · · · · · · · · · · · · · · · · · ·</td> <td>(MAMP</td> <td></td> <td>-</td> <td></td> <td></td> <td></td> <td>-</td> <td></td> <td>97.5% (82% - 100%)</td>	P	ERFO	RMANC	E CHARACT	ERISTICS					000								· · · · · · · · · · · · · · · · · · ·	(MAMP		-				-		97.5% (82% - 100%)
Number														-				· · · · · · · · · · · · · · · · · · ·	, (1000)		+		<u> </u>	-			100% (84.5% - 100%) 95% (79.5% - 100%)
1 1	<u>A</u>	DULTE	RATIO	N CONTROL	<u></u>					(100)								· · · · · · · · · · · · · · · · · · ·	(,		+					-	100% (84.5% - 100%)
Image: product or start is not be to product of the product of th	F	vnecte	d Resu	lts											11						-	÷	-			-	95% (79.5% - 100%)
<form></form>	-			110							Vie	wer +	0	0	2	30	10	100% (91.2% - 100%)	MOP/O	Viewer	+	0	0	2	28	12	100% (91.2% - 100%)
Photo Picture	С	reatini	ne (CR)	: Creatinine r	reacts with	a creatinine i	ndicator in an al	Ikaline mediu	im to form a purplish-brown		C	-	10	18	10	0	0	95% (83.5% - 98.6%)	PI100	А	-	10	16	12	0	0	95% (83.5% - 98.6%)
												wer +	0	0	2	11	29	100% (84.5% -100%)			+	0	0	3	28	12	100% (91.2% - 100%)
<text> Note of a bias of a bia bia bia bia bia bia bia bia bia b</text>										(300)	A	· -			18			· · · · · · · · · · · · · · · · · · ·		В	-	10	16			-	92.5% (80.1% - 97.4%)
Notable bitsNotable bits </td <td>pr</td> <td>roauce</td> <td>s a very</td> <td>light, or no pa</td> <td>ad color cr</td> <td>nange, which i</td> <td>ndicates adulter</td> <td>ation in the to</td> <td>orm of specimen dilution.</td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td> <td>· · · · · · · · · · · · · · · · · · ·</td> <td></td> <td></td> <td>+</td> <td></td> <td>-</td> <td></td> <td></td> <td>-</td> <td>100% (91.2% - 100%)</td>	pr	roauce	s a very	light, or no pa	ad color cr	nange, which i	ndicates adulter	ation in the to	orm of specimen dilution.									· · · · · · · · · · · · · · · · · · ·			+		-			-	100% (91.2% - 100%)
Number of plane by the property of plane by the pla	G	lutaral	dehvde	(GL): Glutara	aldehvde i	s not a natura	component of h	numan urine a	and it should not be present									· · · · · · · · · · · · · · · · · · ·			-				-	-	95% (83.5% - 98.6%)
Image: A mode and a mode and a large and large and large and a large and a large and a large an																		· · · · · · · · · · · · · · · · · · ·			+		<u> </u>	-			100% (84.5% - 100%) 95% (79.5% - 100%)
 	H	oweve	r, false	positive may	result whe	en ketone bod	lies are present	in urine. Ket	tone bodies may appear in	сот								· · · · · · · · · · · · · · · · · · ·	1 1000	Viewer	+				-	-	100% (84.5% - 100%)
<form> n</form>	ur	rine wh	en a pe	rson is in keto	oacidosis,	starvation or c	other metabolic a	abnormalities	i.												-	10	-			-	95% (79.5% - 100%)
		iánián (I	A 146	orrado mitalita in			t of uning mitnite	lavala of un	to 2.6 mm/dl. may be found		Vie	wer +	0	0	1	28	10	95% (84.5% - 100%)		Viewer	+	0	0	1	20	20	100% (84.5% - 100%)
 Absolutional organizational conditional organizational organizatio organizational organizational organizational organizational o				-							E	-	10	10	19	2	0	97.5% (82% - 100%)		С	-	10	19	10	0	0	97.5% (82% - 100%)
b 0									,									, , , , , , , , , , , , , , , , , , , ,			+		•				100% (91.2% - 100%)
bit we we description of a weak weak weak weak weak weak weak we																		, , , , , , , , , , , , , , , , , , , ,	(200)		-				-	-	95% (83.5% - 98.6%)
Note shows in solutions where is a constraint in solution in the solutin the solution in the solution in the s																		, , ,			+		-				100% (91.2% - 100%)
 A P - A P				•	-				oxidizing reagents include	(100)								· · · · · · · · · · · · · · · · · · ·			-				-	-	95% (83.5% - 98.6%)
Note	H	yaroge	en Perox	lide, Ferricyar	nue, Persi	mate, Pyridini	un Chiorochron	iate etc.						-				, , , , , , , , , , , , , , , , , , , ,			- T		<u> </u>		-		100% (91.2% - 100%) 97.5% (87.1% - 99.6)
NameNorm </td <td>p</td> <td>H (PH)</td> <td>: Norma</td> <td>al urine pH ra</td> <td>anges from</td> <td>n 4.5 to 8.0. \</td> <td>Values below nH</td> <td>H 4.0 or abo</td> <td>ve pH 9.0 are indicative of</td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td> <td>· · · · · · · · · · · · · · · · · · ·</td> <td>MTD</td> <td>-</td> <td>+</td> <td></td> <td></td> <td></td> <td>-</td> <td>-</td> <td>100% (84.5% - 100%)</td>	p	H (PH)	: Norma	al urine pH ra	anges from	n 4.5 to 8.0. \	Values below nH	H 4.0 or abo	ve pH 9.0 are indicative of									· · · · · · · · · · · · · · · · · · ·	MTD	-	+				-	-	100% (84.5% - 100%)
Note which is introver and which we have here in a finite we have here is a second of a part of a pa				in prote	5				,									· · · · · · · · · · · · · · · · · · ·			-	-	-				97.5% (82% - 100%)
No. No. <td></td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td> <td>EDDP</td> <td>P Vie</td> <td>wer +</td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td> <td>Viewer</td> <td>+</td> <td></td> <td></td> <td></td> <td>-</td> <td>-</td> <td>100% (84.5% - 100%)</td>										EDDP	P Vie	wer +								Viewer	+				-	-	100% (84.5% - 100%)
is a law betwee sources are all weight or game and all												-	10	18	10	1	0	95% (83.5% - 98.6%)			-	10	12	16		-	95% (79.5% - 100%)
No. Jest								-			Vie	wer +	0	0	1	29	10	97.5% (91.2% - 100%)			+	0	0	1	19	21	100% (84.5% - 100%)
Designed								ie of nigher i	ionic concentration. A urine									· · · · · · · · · · · · · · · · · · ·		С	-				-	-	97.5% (82% - 100%)
Number Numer Numer Numer <td>oł</td> <td>Jecilic</td> <td>gravity t</td> <td></td> <td></td> <td>023 15 CONSIDE</td> <td>ered abriorniai</td> <td></td> <td>OPI</td> <td></td> <td>+</td> <td></td> <td>-</td> <td></td> <td></td> <td>-</td> <td>100% (84.5% - 100%)</td>	oł	Jecilic	gravity t			023 15 CONSIDE	ered abriorniai												OPI		+		-			-	100% (84.5% - 100%)
Next No No No No No<	D	RUG T	EST:							E+C	-							· · · · · · · · · · · · · · · · · · ·			-				-	-	97.5% (82% - 100%)
Processes Processes Processes Processes <th< td=""><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td>ElG</td><td></td><td>wei +</td><td></td><td></td><td></td><td></td><td></td><td>, , ,</td><td></td><td></td><td>Ŧ</td><td></td><td><u> </u></td><td></td><td></td><td></td><td>100% (84.5% - 100%) 97.5% (82% - 100%)</td></th<>										ElG		wei +						, , ,			Ŧ		<u> </u>				100% (84.5% - 100%) 97.5% (82% - 100%)
 Ab	Α	ccurac	сy								Vie	wer +						· · · · · · · · · · · · · · · · · · ·			+				-	-	100% (84.5% - 100%)
 Lab ex nucl y mby there were subset or subset y and y mby subset y	3(040 (ei	abty of	each drug) ur	rine snecin	nens were an:	alvzed by GC-M	IS and by ear	ch corresponding drug test									, , ,			-	10	20	9			97.5% (82% - 100%)
N N											Vie	wer +	0	0	0	18	21	97.5% (82% - 100%)	охү	Viewer	+	0	0	1	19	21	100% (84.5% - 100%)
Phy Phy <td>Le</td> <td>ess tha</td> <td>an Half</td> <td>the Cutoff, No</td> <td>ear Cutoff</td> <td>Negative, Ne</td> <td>ar Cutoff Positi</td> <td>ve, and High</td> <td>Positive. Results were as</td> <td></td> <td>C</td> <td>- (</td> <td>10</td> <td>12</td> <td>18</td> <td>1</td> <td>0</td> <td>100% (84.5% - 100%)</td> <td></td> <td>А</td> <td>-</td> <td>10</td> <td>20</td> <td>9</td> <td>0</td> <td>0</td> <td>97.5% (82% - 100%)</td>	Le	ess tha	an Half	the Cutoff, No	ear Cutoff	Negative, Ne	ar Cutoff Positi	ve, and High	Positive. Results were as		C	- (10	12	18	1	0	100% (84.5% - 100%)		А	-	10	20	9	0	0	97.5% (82% - 100%)
Image Image <t< td=""><td>fo</td><td>llows:</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td>Vie</td><td>wer +</td><td></td><td></td><td>1</td><td>18</td><td>22</td><td>· · · · · · · · · · · · · · · · · · ·</td><td></td><td></td><td>+</td><td>-</td><td>•</td><td>1</td><td></td><td></td><td>100% (84.5% - 100%)</td></t<>	fo	llows:									Vie	wer +			1	18	22	· · · · · · · · · · · · · · · · · · ·			+	-	•	1			100% (84.5% - 100%)
Image <		Drug	Result	Drug	Less	Near	Near Cutoff	High	% Agreement with GC/MS	(20)			1 1					· · · · · · · · · · · · · · · · · · ·			-					-	97.5% (82% - 100%)
		Test		Free	than	Cutoff	Positive	Positive	or LC/MS												+	÷	-			-	100% (84.5% - 100%) 97.5% (82% - 100%)
k k					Half	-			(95%CI)									· · · · ·	PCP	-	+				-		100% (84.5% - 100%)
N N																		· · · · · · · · · · · · · · · · · · ·			-						97.5% (82% - 100%)
N N					Cutom					FTY	Vie	wer +				21	19	· · · · · · · · · · · · · · · · · · ·		Viewer	+					22	100% (84.5% - 100%)
Norm 0							,	,		(100)	A	-	8	15	16	0	0	97.5% (82.12% - 99.6%)		В	-	10	13	15	0	0	95% (79.5% - 100%)
N N						the cutoff)									1			, , ,			+	÷	-			-	100% (84.5% - 100%)
Image Image <th< td=""><td></td><td></td><td>Viewer</td><td></td><td>-</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td>-</td><td></td><td></td><td></td><td></td><td>· · · · · · · · · · · · · · · · · · ·</td><td>DOV</td><td>-</td><td>-</td><td></td><td></td><td></td><td>-</td><td>-</td><td>97.5% (82% - 100%)</td></th<>			Viewer		-								-					· · · · · · · · · · · · · · · · · · ·	DOV	-	-				-	-	97.5% (82% - 100%)
Ner No	(3	500)	A		1			-										· · · · · · · · · · · · · · · · · · ·	PPX		+	÷	-			-	100% (84.5% -100%) 95% (79.5% - 100%)
i i					1				· · · · · · · · · · · · · · · · · · ·	K2								· · · · · · · · · · · · · · · · · · ·			-+				-	-	100% (84.5% -100%)
C -			5						· · · · · · · · · · · · · · · · · · ·									· · · · · · · · · · · · · · · · · · ·				÷	-			-	95% (79.5% - 100%)
New i 0 0 0 0 000000000000000000000000000000000000									· · · · · · · · · · · · · · · · · · ·											Viewer	+				-		100% (84.5% -100%)
N I	A	MP	Viewer		1				· · · · · · · · · · · · · · · · · · ·		E	-	10	12	18	1	0	100% (84.5% - 100%)		С	-	10	10	18	0	0	95% (79.5% - 100%)
B B C	(5	500)	А	- 10	17	11	0	0	95% (83.5% - 98.6%)									· · · · · ·	ТСА		+	÷					100% (84.5% - 100%)
Image i 0 0 2 0 100% (0.15% - 100%) Image 0 0 1 0 0 00% (0.25% - 100%) 0 <td></td> <td></td> <td>Viewer</td> <td></td> <td></td> <td></td> <td></td> <td>10</td> <td>100% (91.2% - 100%)</td> <td></td> <td>_</td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td> <td>· · · · · · · · · · · · · · · · · · ·</td> <td></td> <td></td> <td>-</td> <td></td> <td></td> <td></td> <td>-</td> <td></td> <td>97.5% (82% - 100%)</td>			Viewer					10	100% (91.2% - 100%)		_							· · · · · · · · · · · · · · · · · · ·			-				-		97.5% (82% - 100%)
Image: constraint of the			_						· · · · · · · · · · · · · · · · · · ·									· · · · · · · · · · · · · · · · · · ·			+	÷	-			-	100% (84.5% - 100%)
Nom i 0 0 0 0 1 1 29 100% (d 4 %). 100%) Nom A i 0 0 1 1 29 100% (d 4 %). 100%) Nom A 0 0 2 11 0 0 55% (d 5 %). 100%) 18 2 10				-					· · · · · · · · · · · · · · · · · · ·	(300)							-	· · · · · · · · · · · · · · · · · · ·		-	-						95% (79.5% - 100%) 100% (84.5% - 100%)
here i 1 0 0 97.5% (2%-100%) here i 0 0 2 11 29 97.5% (2%-100%) 0 18 27.5% (2%-100%) 16 0 10 18 0 100% (84.5%-100%) here i 0 0 2 11 29 100% (84.5%-100%) 10 12 18 1 0 00% (84.5%-100%) 10% 12 18 2 00% (84.5%-100%) 10% 12 18 2 0 0 1 <th1< th=""> <th1< th=""></th1<></th1<>		MD	-		1				· · · · · · · · · · · · · · · · · · ·												- T	÷				-	100% (84.5% - 100%) 97.5% (82% - 100%)
News + 0			A		1				· · · · · · · · · · · · · · · · · · ·									· · · · · · · · · · · · · · · · · · ·	тнс		+					-	97.5% (82% - 100%)
B - 10 18 10 0 95% (72.5%, 100%) Newr + 0 0 2 17 21 95% (72.5%, 100%) - 0 0 1 18 22 100 Newr + 0 0 2 100 10 18 2 100 10 18 2 100 10 18 2 00 0 2 0 0 1 18 2 0 <td></td> <td>000)</td> <td></td> <td></td> <td>1</td> <td></td> <td></td> <td></td> <td>· · · · · · · · · · · · · · · · · · ·</td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td> <td>· · · · · · · · · · · · · · · · · · ·</td> <td></td> <td></td> <td>-</td> <td>-</td> <td>-</td> <td></td> <td></td> <td>1</td> <td>97.5% (82% - 100%)</td>		000)			1				· · · · · · · · · · · · · · · · · · ·									· · · · · · · · · · · · · · · · · · ·			-	-	-			1	97.5% (82% - 100%)
New - 0 0 2 11 29 00% (84.5% - 100%) C - 10 18 10 0 0 95% (95% - 100%) 10 18 10 10 18 10 0 95% (95% - 100%) 10 18 10 0 100% (84.5% - 100%) 10 18 10 0 75% (82% - 100%) 10 12 18 1 0 75% (82% - 100%) 10 12 13 10 10 13 21 75% (82% - 100%) 10 12 13 10 0 75% (82% - 100%) 10 12 13 10 10 12 10 12 13 10 10 12 10 11 10 2 20 10 12 13 10 <th1< td=""><td></td><td>000)</td><td>Viewer</td><td>+ 0</td><td></td><td></td><td></td><td></td><td>· · · · · · · · · · · · · · · · · · ·</td><td>KET</td><td>Vie</td><td>wer +</td><td></td><td></td><td></td><td>17</td><td>21</td><td>· · · · · · · · · · · · · · · · · · ·</td><td></td><td>Viewer</td><td>+</td><td></td><td></td><td></td><td>18</td><td>-</td><td>100% (84.5% - 100%)</td></th1<>		000)	Viewer	+ 0					· · · · · · · · · · · · · · · · · · ·	KET	Vie	wer +				17	21	· · · · · · · · · · · · · · · · · · ·		Viewer	+				18	-	100% (84.5% - 100%)
BAR Newer + 0 0 2 20 100% (84.5%-100%) Mewer + 0 0 2 20 00% (84.5%-100%) A - 10 10 18 0 0 95% (25%-100%) B - 10 10 18 0 0 95% (25%-100%) Mewer + 0 0 2 200 00% (84.5%-100%) 10% (84.5%-100%) Mewer + 0 0 2 200 95% (25%-100%) 10% 12 18 1 0 100% (84.5%-100%) Mewer + 0 0 2 20 200 100% (84.5%-100%) 10% 18 0 0 1 10 0 0 2 200 100% (84.5%-100%) 10% 10 10 10 10 10 10 10 10 10 10 10 10 10 10 10 10 10 0		1000)							· · · · · · · · · · · · · · · · · · ·	(1000)) A	-			16		0	95% (84.5% - 100%)		В	-	10	12	17	0	0	97.5% (82% - 100%)
NH NH 1 0 0 1 1 0		1000)	В	- 10	0		0	0	95% (79.5% - 100%)									, , ,			+		-				100% (84.5% - 100%)
Image Image <th< td=""><td></td><td>1000)</td><td>В</td><td>- 10 + 0 - 10</td><td>1</td><td></td><td>0</td><td>1</td><td></td><td>1</td><td>I E</td><td></td><td>10</td><td></td><td></td><td></td><td></td><td>· · · · · · · · · · · · · · · · · · ·</td><td></td><td></td><td>-</td><td></td><td></td><td></td><td>-</td><td>-</td><td>97.5% (82% - 100%)</td></th<>		1000)	В	- 10 + 0 - 10	1		0	1		1	I E		10					· · · · · · · · · · · · · · · · · · ·			-				-	-	97.5% (82% - 100%)
Norm Norm <th< td=""><td>(1</td><td>,</td><td>B Viewer C</td><td>- 10 + 0 - 10 + 0</td><td>18 0</td><td>2</td><td>20</td><td></td><td>· · · · · · · · · · · · · · · · · · ·</td><td></td><td></td><td></td><td></td><td>0</td><td></td><td></td><td>21</td><td>97.5% (82% - 100%)</td><td>THC</td><td></td><td>+</td><td>0</td><td>-</td><td></td><td>20</td><td>20</td><td>100% (91.2% - 100%)</td></th<>	(1	,	B Viewer C	- 10 + 0 - 10 + 0	18 0	2	20		· · · · · · · · · · · · · · · · · · ·					0			21	97.5% (82% - 100%)	THC		+	0	-		20	20	100% (91.2% - 100%)
Image: bit weight in the state of	(1	,	B Viewer C Viewer A	- 10 + 0 - 10 + 0 - 10	18 0 10	2 18	20 0	0	95% (79.5% - 100%)			wer +					0	, , ,		A .		4.0		4.5	^	^	050/ (00 50/ 00 00/)
Normal Participant Normal	(1	,	B Viewer C Viewer A	- 10 + 0 - 10 + 0 - 10 + 0 + 0	18 0 10 0	2 18 2	20 0 20	0 20	95% (79.5% - 100%) 100% (84.5% -100%)	KPA	0	wer +	10	12	18	1		100% (84.5% - 100%)			-				-	-	95% (83.5% - 98.6%) 100% (91.2% - 100%)
BUP Viewer + 0 0 1 1 0 0 0 0 0 1 1 0<	(1	,	B Viewer C Viewer A Viewer B	- 10 + 0 - 10 + 0 - 10 + 0 + 0 - 10	18 0 10 0 10	2 18 2 18	20 0 20 0	0 20 0	95% (79.5% - 100%) 100% (84.5% -100%) 95% (79.5% - 100%)	KRA	Vie	wer + ; - wer +	10 0	12 0	18 2	1 20	20	100% (84.5% - 100%) 100% (84.5% - 100%)		Viewer	- +	0	0	1	20	20	100% (91.2% - 100%)
A - 10 18 11 0 0 97.5% (82% - 100%) Viewer + 0 0 1 16 24 100% (84.5% - 100%) B - 10 18 11 0 0 97.5% (82% - 100%) Viewer + 0 0 2 20 20 100% (84.5% - 100%) B - 10 18 11 0 0 97.5% (82% - 100%) Viewer + 0 0 2 20 20 100% (84.5% - 100%) Viewer + 0 0 2 20 20 100% (84.5% - 100%) MDA (iewer + 0 0 2 20 20 100% (84.5% - 100%) MDA (iewer + 0 0 2 20 20 100% (84.5% - 100%) MEA - 10 10 18 0 0 95% (79.5% - 100%) 10 18 0 <t< td=""><td>(1</td><td>,</td><td>B Viewer C Viewer A Viewer B Viewer</td><td>- 10 + 0 - 10 + 0 - 10 + 0 - 10 + 0 + 0</td><td>18 0 10 0 10 0</td><td>2 18 2 18 2</td><td>20 0 20 0 20</td><td>0 20 0 20</td><td>95% (79.5% - 100%) 100% (84.5% -100%) 95% (79.5% - 100%) 100% (84.5% -100%)</td><td>KRA</td><td>Vie A</td><td>wer + wer + -</td><td>10 0 10</td><td>12 0 10</td><td>18 2 18</td><td>1 20 0</td><td>20 0</td><td>100% (84.5% - 100%) 100% (84.5% - 100%) 95% (79.5% - 100%)</td><td></td><td>Viewer B</td><td>- + - +</td><td>0 10</td><td>0 13</td><td>1 16</td><td>20 0</td><td>20 0</td><td>· · · · · · · · · · · · · · · · · · ·</td></t<>	(1	,	B Viewer C Viewer A Viewer B Viewer	- 10 + 0 - 10 + 0 - 10 + 0 - 10 + 0 + 0	18 0 10 0 10 0	2 18 2 18 2	20 0 20 0 20	0 20 0 20	95% (79.5% - 100%) 100% (84.5% -100%) 95% (79.5% - 100%) 100% (84.5% -100%)	KRA	Vie A	wer + wer + -	10 0 10	12 0 10	18 2 18	1 20 0	20 0	100% (84.5% - 100%) 100% (84.5% - 100%) 95% (79.5% - 100%)		Viewer B	- + - +	0 10	0 13	1 16	20 0	20 0	· · · · · · · · · · · · · · · · · · ·
View + 0 0 1 16 24 100% (84.5% - 100%) B - 10 18 11 0.0 0.0 97.5% (82% - 100%) View + 0 0.0 2.2 100% (84.5% - 100%) 2.0 100% (84.5% - 100%) 2.0 100% (84.5% - 100%) 100 12 10 18 0.0 0.0 95% (79.5% - 100%) 100% 10 18 0.0 0.0 95% (79.5% - 100%) 10 10 18 0.0 0.0 95% (79.5% - 100%) 10 12 10 10 18 0.0 0.0 95% (79.5% - 100%) 10 18 0.0 0.0 95% (79.5% - 100%) 10 12 10 10 10 10 10 10 10 10 10 100 </td <td>(1 В</td> <td>AR</td> <td>B Viewer C Viewer A Viewer B Viewer C</td> <td>- 10 + 0 - 10 + 0 - 10 + 0 - 10 + 0 - 10 + 0 - 10</td> <td>18 0 10 0 10 0 10</td> <td>2 18 2 18 2 18 2 18</td> <td>20 0 20 0 20 0</td> <td>0 20 0 20 0</td> <td>95% (79.5% - 100%) 100% (84.5% -100%) 95% (79.5% - 100%) 100% (84.5% -100%) 95% (79.5% - 100%)</td> <td>KRA</td> <td>Vie A Vie</td> <td>wer + wer + wer + wer + wer +</td> <td>10 0 10 0</td> <td>12 0 10 0</td> <td>18 2 18 1</td> <td>1 20 0 20</td> <td>20 0 20</td> <td>100% (84.5% - 100%) 100% (84.5% - 100%) 95% (79.5% - 100%) 100% (84.5% - 100%)</td> <td></td> <td>Viewer B Viewer</td> <td>- + - +</td> <td>0 10 0</td> <td>0 13 0</td> <td>1 16 2</td> <td>20 0 20</td> <td>20 0 20</td> <td>100% (91.2% - 100%) 97.5% (87.1% - 99.6%)</td>	(1 В	AR	B Viewer C Viewer A Viewer B Viewer C	- 10 + 0 - 10 + 0 - 10 + 0 - 10 + 0 - 10 + 0 - 10	18 0 10 0 10 0 10	2 18 2 18 2 18 2 18	20 0 20 0 20 0	0 20 0 20 0	95% (79.5% - 100%) 100% (84.5% -100%) 95% (79.5% - 100%) 100% (84.5% -100%) 95% (79.5% - 100%)	KRA	Vie A Vie	wer + wer + wer + wer + wer +	10 0 10 0	12 0 10 0	18 2 18 1	1 20 0 20	20 0 20	100% (84.5% - 100%) 100% (84.5% - 100%) 95% (79.5% - 100%) 100% (84.5% - 100%)		Viewer B Viewer	- + - +	0 10 0	0 13 0	1 16 2	20 0 20	20 0 20	100% (91.2% - 100%) 97.5% (87.1% - 99.6%)
Image: bolic	(1 В	AR	B Viewer C Viewer A Viewer B Viewer C	- 10 + 0 - 10 + 0 - 10 + 0 - 10 + 0 - 10 + 0 - 10 + 0	18 0 10 0 10 0 10 0	2 18 2 18 2 18 18 1	20 0 20 0 20 0 16	0 20 0 20 0 24	95% (79.5% - 100%) 100% (84.5% -100%) 95% (79.5% - 100%) 100% (84.5% -100%) 95% (79.5% - 100%) 100% (84.5% - 100%)	KRA	Vie A Vie E	wer + - - wer + - - wer + - - wer + - -	10 0 10 0 10	12 0 10 0 10	18 2 18 1 19	1 20 0 20 0	20 0 20 0	100% (84.5% - 100%) 100% (84.5% - 100%) 95% (79.5% - 100%) 100% (84.5% - 100%) 97.5% (79.5% - 100%)	(40)	Viewer B Viewer C	- + - + - +	0 10 0 10	0 13 0 13	1 16 2 15	20 0 20 0	20 0 20 0	100% (91.2% - 100%) 97.5% (87.1% - 99.6%) 100% (91.2% - 100%)
New 1 0 0 2 10 24 100 04-34 100 04-34 100 04-34 100 04-34 100 04-34 100 04-34 100 04-34 100 04-34 100 10 18 0 0 95% (79.5% - 100%) B20 A - 10 18 10 0 0 95% (79.5% - 100%) 10 18 0 0 95% (79.5% - 100%) Viewer + 0 0 2 20 10 100 95% (79.5% - 100%) Viewer + 0 0 2 20 20 100% (84.5% - 100%) Viewer + 0 0 2 20 20 100% (84.5% - 100%) 20 12 17 0 0 22 100 11 18 20 95% (79.5% - 100%) Viewer + 0 0 2 21 19 100% (91.2% - 100%) 10 18	(1 В	AR	B Viewer A Viewer B Viewer C Viewer A	- 10 + 0 - 10 + 0 - 10 + 0 - 10 + 0 - 10 + 0 - 10 + 0 - 10	18 0 10 0 10 0 10 0 18	2 18 2 18 2 18 1 1 11	20 0 20 0 20 0 16 0	0 20 0 20 0 24 0	95% (79.5% - 100%) 100% (84.5% - 100%) 95% (79.5% - 100%) 100% (84.5% - 100%) 95% (79.5% - 100%) 100% (84.5% - 100%) 97.5% (82% - 100%)		Vie A Vie Vie Vie	wer + - -	10 0 10 0 10 0 10 10 10 10 10 10	12 0 10 0 10 0 10 10	18 2 18 1 19 2 18	1 20 0 20 0 20 0 0	20 0 20 0 20 0	100% (84.5% - 100%) 100% (84.5% - 100%) 95% (79.5% - 100%) 100% (84.5% - 100%) 97.5% (79.5% - 100%) 100% (84.5% - 100%) 95% (79.5% - 100%)	(40) THC	Viewer B Viewer C Viewer	- + + - + + -	0 10 0 10 0 10	0 13 0 13 0 12	1 16 2 15 1 17	20 0 20 0 18 0	20 0 20 0 22 0 22 0	100% (91.2% - 100%) 97.5% (87.1% - 99.6%) 100% (91.2% - 100%) 95% (83.5% - 98.6%) 100% (84.5% - 100%) 97.5% (82% - 100%)
BZO Niewer H O<	(1 В	AR	B Viewer A Viewer B Viewer C Viewer A Viewer	- 10 + 0 - 10	18 0 10 0 10 0 10 0 10 0 18 0 18 18	2 18 2 18 2 18 1 11 11 11	20 0 20 0 20 0 16 0 16 0	0 20 0 20 0 24 0 24 0 24 0	95% (79.5% - 100%) 100% (84.5% - 100%) 95% (79.5% - 100%) 100% (84.5% - 100%) 95% (79.5% - 100%) 100% (84.5% - 100%) 97.5% (82% - 100%) 100% (84.5% - 100%)		Vie A Vie E Vie C A	Wer + - -	10 0 10 0 10 0 10 0 10 0 10 0 10 0	12 0 10 0 10 0 10 0 10 0	18 2 18 1 19 2 18 2 18 2	1 20 0 20 0 20 0 20 20	20 0 20 0 20 0 20 20	100% (84.5% - 100%) 100% (84.5% - 100%) 95% (79.5% - 100%) 100% (84.5% - 100%) 97.5% (79.5% - 100%) 100% (84.5% - 100%) 95% (79.5% - 100%) 100% (84.5% - 100%)	(40) THC	Viewer B Viewer C Viewer A Viewer	- + - + - + - + -	0 10 0 10 0 10 0 0	0 13 0 13 0 12 0	1 16 2 15 1 17 17 1	20 0 20 0 18 0 18	20 0 20 0 22 0 22 0 22	100% (91.2% - 100%) 97.5% (87.1% - 99.6%) 100% (91.2% - 100%) 95% (83.5% - 98.6%) 100% (84.5% - 100%) 97.5% (82% - 100%) 100% (84.5% - 100%)
b2c viewer i 0 0 2 1 0<	(1 В	AR	B Viewer C Viewer B Viewer C Viewer A Viewer B Viewer	- 10 + 0 - 10 + 0 - 10 + 0 - 10 + 0 - 10 + 0 - 10 + 0 - 10 + 0 - 10 + 0 - 10 + 0	18 0 10 0 10 0 10 0 18 0 18 0	2 18 2 18 2 18 1 11 11 11 2	20 0 20 0 20 0 16 0 16 0 16	0 20 0 24 0 24 0 24 0 24	95% (79.5% - 100%) 100% (84.5% - 100%) 95% (79.5% - 100%) 100% (84.5% - 100%) 95% (79.5% - 100%) 100% (84.5% - 100%) 97.5% (82% - 100%) 100% (84.5% - 100%) 100% (84.5% - 100%) 100% (84.5% - 100%) 100% (84.5% - 100%) 100% (84.5% - 100%)		Vie Vie Vie Vie C Vie C	wer + . - wer + . -	10 0 10 0 10 0 10 0 10 0 10 0 10 0 10 0 10 0 10	12 0 10 0 10 0 10 0 10 0 10	18 2 18 1 19 2 18 2 18 2 18	1 20 0 20 0 20 0 20 0 20 0	20 0 20 0 20 0 20 0 20 0	100% (84.5% - 100%) 100% (84.5% - 100%) 95% (79.5% - 100%) 100% (84.5% - 100%) 97.5% (79.5% - 100%) 100% (84.5% - 100%) 95% (79.5% - 100%) 95% (79.5% - 100%) 95% (79.5% - 100%)	(40) THC	Viewer B Viewer C Viewer A Viewer B	- + - + + - + + - + - + -	0 10 0 10 0 10 0 10 0	0 13 0 13 0 12 0 12	1 16 2 15 1 17 17 17	20 0 20 0 18 0 18 0	20 0 20 0 22 0 22 0 22 0	100% (91.2% - 100%) 97.5% (87.1% - 99.6%) 100% (91.2% - 100%) 95% (83.5% - 98.6%) 100% (84.5% - 100%) 97.5% (82% - 100%) 100% (84.5% - 100%) 97.5% (82% - 100%)
Normalize Normalize <t< td=""><td>(1 </td><td>AR UP</td><td>B Viewer A Viewer B Viewer C Viewer A Viewer B Viewer C</td><td>- 10 + 0 - 10 + 0 - 10 + 0 - 10 + 0 - 10 + 0 - 10 + 0 - 10 + 0 - 10 + 0 - 10 + 0 - 10</td><td>18 0 10 0 10 0 10 0 18 0 18 0 18</td><td>2 18 2 18 2 18 1 1 1 1 1 2 10</td><td>20 0 20 0 16 0 16 0 16 0</td><td>0 20 0 20 0 24 0 24 0 24 0 24 0</td><td>95% (79.5% - 100%) 100% (84.5% - 100%) 95% (79.5% - 100%) 100% (84.5% - 100%) 95% (79.5% - 100%) 100% (84.5% - 100%) 97.5% (82% - 100%) 100% (84.5% - 100%) 97.5% (82% - 100%) 100% (84.5% - 100%) 97.5% (82% - 100%) 97.5% (82% - 100%) 97.5% (82% - 100%) 97.5% (79.5% - 100%)</td><td></td><td>Vie Vie Vie Vie Vie Vie Vie Vie</td><td>wer + > - wer + - wer + - wer + -</td><td>10 0 10 0 10 0 10 0 10 0 10 0 10 0 10 0 10 0 10 0</td><td>12 0 10 0 10 0 10 0 10 0 10 0</td><td>18 2 18 1 19 2 18 2 18 2 18 2</td><td>1 20 0 20 0 20 0 20 0 20 0 20</td><td>20 0 20 0 20 0 20 0 20 0 20</td><td>100% (84.5% - 100%) 100% (84.5% - 100%) 95% (79.5% - 100%) 100% (84.5% - 100%) 97.5% (79.5% - 100%) 100% (84.5% - 100%) 95% (79.5% - 100%) 100% (84.5% - 100%) 95% (79.5% - 100%) 100% (84.5% - 100%) 100% (84.5% - 100%) 95% (79.5% - 100%) 100% (84.5% - 100%)</td><td>(40) THC</td><td>Viewer B Viewer C Viewer A Viewer B Viewer</td><td>- + - + - + - + - + + -</td><td>0 10 0 10 0 10 0 10 0 0</td><td>0 13 0 13 0 12 0 12 0 12 0</td><td>1 16 2 15 1 17 1 17 17 1</td><td>20 0 20 18 0 18 0 18 0</td><td>20 0 20 0 22 0 22 0 22 0 22 22</td><td>100% (91.2% - 100%) 97.5% (87.1% - 99.6%) 100% (91.2% - 100%) 95% (83.5% - 98.6%) 100% (84.5% - 100%) 97.5% (82% - 100%) 100% (84.5% - 100%) 97.5% (82% - 100%) 100% (84.5% - 100%) 97.5% (82% - 100%) 100% (84.5% - 100%)</td></t<>	(1 	AR UP	B Viewer A Viewer B Viewer C Viewer A Viewer B Viewer C	- 10 + 0 - 10 + 0 - 10 + 0 - 10 + 0 - 10 + 0 - 10 + 0 - 10 + 0 - 10 + 0 - 10 + 0 - 10	18 0 10 0 10 0 10 0 18 0 18 0 18	2 18 2 18 2 18 1 1 1 1 1 2 10	20 0 20 0 16 0 16 0 16 0	0 20 0 20 0 24 0 24 0 24 0 24 0	95% (79.5% - 100%) 100% (84.5% - 100%) 95% (79.5% - 100%) 100% (84.5% - 100%) 95% (79.5% - 100%) 100% (84.5% - 100%) 97.5% (82% - 100%) 100% (84.5% - 100%) 97.5% (82% - 100%) 100% (84.5% - 100%) 97.5% (82% - 100%) 97.5% (82% - 100%) 97.5% (82% - 100%) 97.5% (79.5% - 100%)		Vie Vie Vie Vie Vie Vie Vie Vie	wer + > - wer + - wer + - wer + -	10 0 10 0 10 0 10 0 10 0 10 0 10 0 10 0 10 0 10 0	12 0 10 0 10 0 10 0 10 0 10 0	18 2 18 1 19 2 18 2 18 2 18 2	1 20 0 20 0 20 0 20 0 20 0 20	20 0 20 0 20 0 20 0 20 0 20	100% (84.5% - 100%) 100% (84.5% - 100%) 95% (79.5% - 100%) 100% (84.5% - 100%) 97.5% (79.5% - 100%) 100% (84.5% - 100%) 95% (79.5% - 100%) 100% (84.5% - 100%) 95% (79.5% - 100%) 100% (84.5% - 100%) 100% (84.5% - 100%) 95% (79.5% - 100%) 100% (84.5% - 100%)	(40) THC	Viewer B Viewer C Viewer A Viewer B Viewer	- + - + - + - + - + + -	0 10 0 10 0 10 0 10 0 0	0 13 0 13 0 12 0 12 0 12 0	1 16 2 15 1 17 1 17 17 1	20 0 20 18 0 18 0 18 0	20 0 20 0 22 0 22 0 22 0 22 22	100% (91.2% - 100%) 97.5% (87.1% - 99.6%) 100% (91.2% - 100%) 95% (83.5% - 98.6%) 100% (84.5% - 100%) 97.5% (82% - 100%) 100% (84.5% - 100%) 97.5% (82% - 100%) 100% (84.5% - 100%) 97.5% (82% - 100%) 100% (84.5% - 100%)
B - 10 18 11 0 0 97.5% (\$7.1% - 99.6%) Viewer + 0 0 2 10 11 10 0 97.5% (\$7.1% - 99.6%) Viewer + 0 0 2 11 10 0 97.5% (\$7.1% - 99.6%) Viewer + 0 0 2 11 17 0 0 95% (\$8.5% - 98.6%) Ba - 10 11 17 0 0 95% (\$8.5% - 98.6%) Ba - 0 0 2 21 19 100% (91.2% - 100%) 95% (\$7.1% - 99.6%) <t< td=""><td>(1 В В</td><td>AR UP ZO</td><td>B Viewer A Viewer B Viewer C Viewer A Viewer B Viewer C</td><td>- 10 + 0 - 10 + 0 - 10 + 0 - 10 + 0 - 10 + 0 - 10 + 0 - 10 + 0 - 10 + 0 - 10 + 0 - 10 + 0 - 10 + 0</td><td>18 0 10 0 10 0 10 0 10 0 18 0 18 0 18 0</td><td>2 18 2 18 2 18 1 1 1 1 1 2 10 2</td><td>20 0 20 0 16 0 16 0 16 0 22</td><td>0 20 0 20 0 24 0 24 0 24 0 24 0 18</td><td>95% (79.5% - 100%) 100% (84.5% - 100%) 95% (79.5% - 100%) 100% (84.5% - 100%) 95% (79.5% - 100%) 100% (84.5% - 100%) 97.5% (82% - 100%) 100% (84.5% - 100%) 97.5% (82% - 100%) 100% (84.5% - 100%) 97.5% (82% - 100%) 100% (84.5% - 100%) 95% (79.5% - 100%) 100% (84.5% - 100%) 100% (84.5% - 100%) 95% (79.5% - 100%) 100% (91.2% - 100%)</td><td></td><td>Vie Vie Vie Vie Vie Vie Vie Vie E</td><td>wer + - wer + -</td><td>10 0 10 0 10 0 10 0 10 0 10 0 10 0 10 0 10 0 10 0 10 0</td><td>12 0 10 0 10 0 10 0 10 0 10 0 10</td><td>18 2 18 1 19 2 18 2 18 2 18 2 18</td><td>1 20 0 20 0 20 0 20 0 20 0 20 0 20 0</td><td>20 0 20 0 20 0 20 0 20 0 20 0</td><td>100% (84.5% - 100%) 100% (84.5% - 100%) 95% (79.5% - 100%) 100% (84.5% - 100%) 97.5% (79.5% - 100%) 100% (84.5% - 100%) 95% (79.5% - 100%) 100% (84.5% - 100%) 95% (79.5% - 100%) 100% (84.5% - 100%) 95% (79.5% - 100%) 95% (79.5% - 100%) 95% (79.5% - 100%) 95% (79.5% - 100%) 95% (79.5% - 100%)</td><td>(40) THC (50)</td><td>Viewer B Viewer C Viewer A Viewer B Viewer C</td><td>- + - + - + - + - + - + - + - + +</td><td>0 10 0 10 0 10 0 10 0 10 0 10</td><td>0 13 0 13 0 12 0 12 0 12 0 12 0 12</td><td>1 16 2 15 1 17 1 17 1 17 1 17</td><td>20 0 20 18 0 18 0 18 0 18 0</td><td>20 0 20 0 22 0 22 0 22 0 22 0 0</td><td>100% (91.2% - 100%) 97.5% (87.1% - 99.6%) 100% (91.2% - 100%) 95% (83.5% - 98.6%) 100% (84.5% - 100%) 97.5% (82% - 100%) 100% (84.5% - 100%) 97.5% (82% - 100%) 97.5% (82% - 100%) 97.5% (82% - 100%) 97.5% (82% - 100%)</td></t<>	(1 В В	AR UP ZO	B Viewer A Viewer B Viewer C Viewer A Viewer B Viewer C	- 10 + 0 - 10 + 0 - 10 + 0 - 10 + 0 - 10 + 0 - 10 + 0 - 10 + 0 - 10 + 0 - 10 + 0 - 10 + 0 - 10 + 0	18 0 10 0 10 0 10 0 10 0 18 0 18 0 18 0	2 18 2 18 2 18 1 1 1 1 1 2 10 2	20 0 20 0 16 0 16 0 16 0 22	0 20 0 20 0 24 0 24 0 24 0 24 0 18	95% (79.5% - 100%) 100% (84.5% - 100%) 95% (79.5% - 100%) 100% (84.5% - 100%) 95% (79.5% - 100%) 100% (84.5% - 100%) 97.5% (82% - 100%) 100% (84.5% - 100%) 97.5% (82% - 100%) 100% (84.5% - 100%) 97.5% (82% - 100%) 100% (84.5% - 100%) 95% (79.5% - 100%) 100% (84.5% - 100%) 100% (84.5% - 100%) 95% (79.5% - 100%) 100% (91.2% - 100%)		Vie Vie Vie Vie Vie Vie Vie Vie E	wer + -	10 0 10 0 10 0 10 0 10 0 10 0 10 0 10 0 10 0 10 0 10 0	12 0 10 0 10 0 10 0 10 0 10 0 10	18 2 18 1 19 2 18 2 18 2 18 2 18	1 20 0 20 0 20 0 20 0 20 0 20 0 20 0	20 0 20 0 20 0 20 0 20 0 20 0	100% (84.5% - 100%) 100% (84.5% - 100%) 95% (79.5% - 100%) 100% (84.5% - 100%) 97.5% (79.5% - 100%) 100% (84.5% - 100%) 95% (79.5% - 100%) 100% (84.5% - 100%) 95% (79.5% - 100%) 100% (84.5% - 100%) 95% (79.5% - 100%) 95% (79.5% - 100%) 95% (79.5% - 100%) 95% (79.5% - 100%) 95% (79.5% - 100%)	(40) THC (50)	Viewer B Viewer C Viewer A Viewer B Viewer C	- + - + - + - + - + - + - + - + +	0 10 0 10 0 10 0 10 0 10 0 10	0 13 0 13 0 12 0 12 0 12 0 12 0 12	1 16 2 15 1 17 1 17 1 17 1 17	20 0 20 18 0 18 0 18 0 18 0	20 0 20 0 22 0 22 0 22 0 22 0 0	100% (91.2% - 100%) 97.5% (87.1% - 99.6%) 100% (91.2% - 100%) 95% (83.5% - 98.6%) 100% (84.5% - 100%) 97.5% (82% - 100%) 100% (84.5% - 100%) 97.5% (82% - 100%) 97.5% (82% - 100%) 97.5% (82% - 100%) 97.5% (82% - 100%)
Image: Normal state Image: Normal state<	(1 В В	AR UP ZO	B Viewer A Viewer B Viewer C Viewer A Viewer C Viewer C Viewer A	- 10 + 0 - 10 + 0 - 10 + 0 - 10 + 0 - 10 + 0 - 10 + 0 - 10 + 0 - 10 + 0 - 10 + 0 - 10 + 0 - 10 + 0 - 10	18 0 10 0 10 0 10 0 10 0 18 0 18 0 18	2 18 2 18 2 18 1 11 11 2 10 2 10	20 0 20 0 16 0 16 0 16 0 22 0	0 20 0 20 0 24 0 24 0 24 0 24 0 24 0 18 0	95% (79.5% - 100%) 100% (84.5% -100%) 95% (79.5% - 100%) 100% (84.5% - 100%) 95% (79.5% - 100%) 100% (84.5% - 100%) 97.5% (82% - 100%) 100% (84.5% - 100%) 97.5% (82% - 100%) 100% (84.5% - 100%) 97.5% (82% - 100%) 100% (84.5% - 100%) 95% (79.5% - 100%) 100% (84.5% - 100%) 95% (79.5% - 100%) 95.0% (83.5% - 98.6%)		Vie Vie Vie Vie Vie Vie Vie Vie Vie	wer + - -	10 0 10 0 10 0 10 0 10 0 10 0 10 0 10 0 10 0 10 0 10 0	12 0 10 0 10 0 10 0 10 0 10 0 10 0	18 2 18 1 19 2 18 2 18 2 18 2 18 2 18 2	1 20 0 20 0 20 0 20 0 20 0 20 0 20 0 20	20 0 20 0 20 0 20 0 20 0 20 0 20	100% (84.5% - 100%) 100% (84.5% - 100%) 95% (79.5% - 100%) 100% (84.5% - 100%) 97.5% (79.5% - 100%) 100% (84.5% - 100%) 95% (79.5% - 100%) 100% (84.5% - 100%) 95% (79.5% - 100%) 100% (84.5% - 100%) 95% (79.5% - 100%) 100% (84.5% - 100%) 95% (79.5% - 100%) 100% (84.5% - 100%) 95% (79.5% - 100%) 100% (84.5% - 100%)	(40) THC (50) TRA	Viewer B Viewer C Viewer A Viewer B Viewer C Viewer	- + + - + + - + - + - + - + - + -	0 10 0 10 0 10 0 10 0 10 0 0	0 13 0 13 0 12 0 12 0 12 0 12 0 12 0 12 0 12 0 12 0 12 0 12 0 12 0 12 0 13 0 13 13 0 13 13 13 13 13 13 13 13 13 13	1 16 2 15 1 17 1 17 1 17 2	20 0 20 18 0 18 0 18 0 18 0 19	20 0 20 0 22 0 22 0 22 0 22 0 22 0 21	100% (91.2% - 100%) 97.5% (87.1% - 99.6%) 100% (91.2% - 100%) 95% (83.5% - 98.6%) 100% (84.5% - 100%) 97.5% (82% - 100%) 100% (84.5% - 100%) 97.5% (82% - 100%) 100% (84.5% - 100%) 97.5% (82% - 100%) 100% (84.5% - 100%)
BZO Viewer + 0 0 2 20 100% (84.5% - 100%) Iso 10 10 11 17 0 0 95% (83.5% - 98.6%) C - 10 10 11 17 0 0 95% (83.5% - 98.6%) C - 10 97.5%	(1 В В	AR UP ZO	B Viewer A Viewer B Viewer C Viewer A Viewer C Viewer A Viewer A Viewer	- 10 + 0 - 10 + 0 - 10 + 0 - 10 + 0 - 10 + 0 - 10 + 0 - 10 + 0 - 10 + 0 - 10 + 0 - 10 + 0 - 10 + 0 - 10 + 0	18 0 10 0 10 0 10 0 18 0 18 0 18 0 18 0	2 18 2 18 2 18 1 11 11 2 10 2 10 1	20 0 20 0 16 0 16 0 16 0 22 0 22	0 20 0 20 0 24 0 24 0 24 0 24 0 24 0 18 0 18	95% (79.5% - 100%) 100% (84.5% - 100%) 95% (79.5% - 100%) 100% (84.5% - 100%) 95% (79.5% - 100%) 100% (84.5% - 100%) 97.5% (82% - 100%) 100% (84.5% - 100%) 97.5% (82% - 100%) 100% (84.5% - 100%) 97.5% (82% - 100%) 100% (84.5% - 100%) 95% (79.5% - 100%) 100% (84.5% - 100%) 95% (79.5% - 100%) 100% (83.5% - 98.6%) 100% (91.2% - 100%)	MDMA	Vie Vie Vie Vie Vie Vie Vie Vie	wer + - - wer + wer + > -	10 0 10 0 10 0 10 0 10 0 10 0 10 0 10 0 10 0 10 0 10 0 10	12 0 10 0 10 0 10 0 10 0 10 0 10	18 2 18 1 19 2 18 2 18 2 18 2 18 2 18 2 18 2 18 2 18 2 18 2 18	1 20 0 20 0 20 0 20 0 20 0 20 0 20 0 20	20 0 20 0 20 0 20 0 20 0 20 0 20 0 0	100% (84.5% - 100%) 100% (84.5% - 100%) 95% (79.5% - 100%) 100% (84.5% - 100%) 97.5% (79.5% - 100%) 100% (84.5% - 100%) 95% (79.5% - 100%) 95% (79.5% - 100%) 100% (84.5% - 100%) 95% (79.5% - 100%) 95% (79.5% - 100%) 95% (79.5% - 100%) 95% (79.5% - 100%) 95% (79.5% - 100%) 95% (79.5% - 100%) 95% (79.5% - 100%) 95% (79.5% - 100%) 95% (79.5% - 100%)	(40) THC (50) TRA	Viewer B Viewer C Viewer A Viewer C Viewer A	- + - + - + - + - + - + - + - + - + - - + -	0 10 0 10 0 10 0 10 0 10 0 10 10	0 13 0 13 0 12 0 12 0 12 0 12 0 12 0 20	1 16 2 15 1 17 1 17 1 17 2 8	20 0 20 18 0 18 0 18 0 18 0 19 0	20 0 20 0 22 0 22 0 22 0 22 0 22 0 21 0	100% (91.2% - 100%) 97.5% (87.1% - 99.6%) 100% (91.2% - 100%) 95% (83.5% - 98.6%) 100% (84.5% - 100%) 97.5% (82% - 100%) 100% (84.5% - 100%) 97.5% (82% - 100%) 97.5% (82% - 100%) 100% (84.5% - 100%) 97.5% (82% - 100%) 100% (84.5% - 100%) 97.5% (82% - 100%) 100% (84.5% - 100%) 97.5% (82% - 100%) 100% (84.5% - 100%)
	(1 В В В	AR UP ZO	B Viewer A Viewer B Viewer C Viewer A Viewer C Viewer A Viewer B	- 10 + 0 - 10 + 0 - 10 + 0 - 10 + 0 - 10 + 0 - 10 + 0 - 10 + 0 - 10 + 0 - 10 + 0 - 10 + 0 - 10 + 0 - 10 + 0 - 10 + 0 - 10	18 0 10 0 10 0 10 0 10 0 10 0 18 0 18 0 18 0 18 0 18 0 18 0 18	2 18 2 18 2 18 1 11 11 2 10 2 10 1 11 11	20 0 20 0 20 0 16 0 16 0 16 0 22 0 22 0	0 20 0 20 0 24 0 24 0 24 0 24 0 24 0 18 0 18 0	95% (79.5% - 100%) 100% (84.5% - 100%) 95% (79.5% - 100%) 100% (84.5% - 100%) 95% (79.5% - 100%) 100% (84.5% - 100%) 97.5% (82% - 100%) 100% (84.5% - 100%) 97.5% (82% - 100%) 100% (84.5% - 100%) 97.5% (82% - 100%) 100% (84.5% - 100%) 95% (79.5% - 100%) 100% (81.5% - 100%) 100% (83.5% - 98.6%) 100% (91.2% - 100%) 97.5% (87.1% - 99.6%)	MDMA	Vie Vie Vie Vie Vie Vie Vie Vie Vie Vie	wer + - -	10 0 10 0 10 0 10 0 10 0 10 0 10 0 10 0 10 0 10 0 10 0 10 0	12 0 10 0 10 0 10 0 10 0 10 0 10 0 0	18 2 18 1 19 2 18 2 18 2 18 2 18 2 18 2 18 2 18 2 18 2 18 2	1 20 0 20 2	20 0 20 0 20 0 20 0 20 0 20 0 20 0 19	100% (84.5% - 100%) 100% (84.5% - 100%) 95% (79.5% - 100%) 100% (84.5% - 100%) 97.5% (79.5% - 100%) 100% (84.5% - 100%) 95% (79.5% - 100%) 100% (84.5% - 100%) 95% (79.5% - 100%) 100% (84.5% - 100%) 95% (79.5% - 100%) 100% (84.5% - 100%) 95% (79.5% - 100%) 100% (84.5% - 100%) 95% (79.5% - 100%) 100% (84.5% - 100%) 95% (79.5% - 100%) 100% (91.2% - 100%)	(40) THC (50) TRA	Viewer B Viewer C Viewer B Viewer C Viewer A Viewer	- - - - - - - - - - - - - - - - - - -	0 10 0 10 0 10 0 10 0 10 0 10 0 0	0 13 0 13 0 12 0 12 0 12 0 12 0 12 0 12 0 12 0 12 0 12 0 12 0 12 0 12 0 13 0 13 13 0 13 13 0 14 15 15 15 15 15 15 15 15 15 15	1 16 2 15 1 17 1 17 1 17 1 17 2 8 1	20 0 20 18 0 18 0 18 0 18 0 19 0 19	20 0 20 0 22 0 22 0 22 0 22 0 22 0 21 0 20	100% (91.2% - 100%) 97.5% (87.1% - 99.6%) 100% (91.2% - 100%) 95% (83.5% - 98.6%) 100% (84.5% - 100%) 97.5% (82% - 100%) 100% (84.5% - 100%) 97.5% (82% - 100%) 100% (84.5% - 100%) 97.5% (82% - 100%) 100% (84.5% - 100%) 97.5% (82% - 100%) 97.5% (82% - 100%) 97.5% (79.5% - 100%)
(300) IA I - I 10 I 10 I 18 I 0 I 0 I 95% (79.5% - 100%) I	(1 В В В	AR UP ZO	B Viewer A Viewer B Viewer C Viewer A Viewer C Viewer A Viewer A Viewer	- 10 + 0 - 10 + 0 - 10 + 0 - 10 + 0 - 10 + 0 - 10 + 0 - 10 + 0 - 10 + 0 - 10 + 0 - 10 + 0 - 10 + 0 - 10 + 0 - 10 + 0 - 10 + 0	18 0 10 0 10 0 10 0 10 0 18 0 18 0 18 0 18 0 18 0 18 0	2 18 2 18 2 18 1 11 11 11 2 10 2 10 1 11 11 11 11	20 0 20 0 20 0 16 0 16 0 16 0 22 0 22 0 22 0 0	0 20 0 20 0 24 0 24 0 24 0 24 0 18 0 18 0 18	95% (79.5% - 100%) 100% (84.5% - 100%) 95% (79.5% - 100%) 100% (84.5% - 100%) 95% (79.5% - 100%) 100% (84.5% - 100%) 97.5% (82% - 100%) 100% (84.5% - 100%) 97.5% (82% - 100%) 100% (84.5% - 100%) 95% (79.5% - 100%) 100% (84.5% - 100%) 95.0% (83.5% - 98.6%) 100% (91.2% - 100%) 97.5% (87.1% - 99.6%) 100% (91.2% - 100%)	MDMA MET (mAMF)	C Vie A Vie C Vie C Vie C Vie Vie	wer + - - wer + - -	10 0 10 0 10 0 10 0 10 0 10 0 10 0 10 0 10 0 10 0 10 0 10 0 10 0	12 0 10 0 10 0 10 0 10 0 10 0 10 0 10 0	18 2 18 1 19 2 18 2 18 2 18 2 18 2 18 2 18 2 17 2	1 20 0 20 2	20 0 20 0 20 0 20 0 20 0 20 0 20 0 20	100% (84.5% - 100%) 100% (84.5% - 100%) 95% (79.5% - 100%) 100% (84.5% - 100%) 97.5% (79.5% - 100%) 100% (84.5% - 100%) 95% (79.5% - 100%) 100% (84.5% - 100%) 95% (79.5% - 100%) 100% (84.5% - 100%) 95% (79.5% - 100%) 100% (84.5% - 100%) 95% (79.5% - 100%) 100% (84.5% - 100%) 95% (79.5% - 100%) 95% (79.5% - 100%) 95% (79.5% - 100%) 95% (79.5% - 100%) 95% (83.5% - 98.6%) 100% (91.2% - 100%)	(40) THC (50) TRA	Viewer B Viewer C Viewer B Viewer C Viewer A Viewer B Viewer B Viewer	- + + - + + - + - - + - - + - - - - + -	0 10 0 10 0 10 0 10 0 10 0 10 0 10 0 1	0 13 0 13 0 12 0 12 0 12 0 12 0 12 0 20 0 20 0 0	1 16 2 15 1 17 1 17 1 17 2 8 1 9 1	20 0 20 18 0 18 0 18 0 18 0 19 0 19 0 19 1 18	20 0 20 0 22 0 22 0 22 0 22 0 22 0 21 0 20 0 20	100% (91.2% - 100%) 97.5% (87.1% - 99.6%) 100% (91.2% - 100%) 95% (83.5% - 98.6%) 100% (84.5% - 100%) 97.5% (82% - 100%) 100% (84.5% - 100%) 97.5% (82% - 100%) 100% (84.5% - 100%) 97.5% (82% - 100%) 100% (84.5% - 100%) 97.5% (82% - 100%) 97.5% (84.5% - 100%) 95% (79.5% - 100%) 97.5% (84.5% - 100%) 97.5% (84.5% - 100%) 97.5% (84.5% - 100%) 97.5% (84.5% - 100%) 97.5% (84.5% - 100%)
	(1 	AR UP ZO 200) ZO	B Viewer A Viewer B Viewer C Viewer B Viewer C Viewer A Viewer B Viewer	- 10 + 0 - 10 + 0 - 10 + 0 - 10 + 0 - 10 + 0 - 10 + 0 - 10 + 0 - 10 + 0 - 10 + 0 - 10 + 0 - 10 + 0 - 10 + 0 - 10 + 0 - 10 + 0 - 10 + 0	18 0 10 0 10 0 10 0 18 0 18 0 18 0 18 0	2 18 2 18 2 18 1 11 11 2 10 2 10 2 10 1 11 11 11 2 10 2 10 11 11 11 2 10 10 10 10 10 10 10 10 10 10	20 0 20 0 20 0 16 0 16 0 16 0 22 0 22 0 22 0 22 0 22 0 22 0 22 0 22 0 22 0 22 0 22 0 20 2	0 20 0 20 0 24 0 24 0 24 0 24 0 18 0 18 0 18 0 20	95% (79.5% - 100%) 100% (84.5% - 100%) 95% (79.5% - 100%) 95% (79.5% - 100%) 95% (79.5% - 100%) 95% (79.5% - 100%) 100% (84.5% - 100%) 97.5% (82% - 100%) 100% (84.5% - 100%) 95% (79.5% - 100%) 95% (79.5% - 100%) 95% (79.5% - 100%) 95% (79.5% - 100%) 90% (83.5% - 98.6%) 100% (91.2% - 100%) 97.5% (87.1% - 99.6%) 100% (81.5% - 100%)	MDMA MET (mAMF)	C Vie A Vie C Vie C Vie C Vie Vie	wer + - - wer + - -	10 0 10 0 10 0 10 0 10 0 10 0 10 0 10 0 10 0 10 0 10 0 10 0 10 0	12 0 10 0 10 0 10 0 10 0 10 0 10 0 10 0	18 2 18 1 19 2 18 2 18 2 18 2 18 2 18 2 18 2 17 2	1 20 0 20 2	20 0 20 0 20 0 20 0 20 0 20 0 20 0 20	100% (84.5% - 100%) 100% (84.5% - 100%) 95% (79.5% - 100%) 100% (84.5% - 100%) 97.5% (79.5% - 100%) 100% (84.5% - 100%) 95% (79.5% - 100%) 100% (84.5% - 100%) 95% (79.5% - 100%) 100% (84.5% - 100%) 95% (79.5% - 100%) 100% (84.5% - 100%) 95% (79.5% - 100%) 100% (84.5% - 100%) 95% (79.5% - 100%) 95% (79.5% - 100%) 95% (79.5% - 100%) 95% (79.5% - 100%) 95% (83.5% - 98.6%) 100% (91.2% - 100%)	(40) THC (50) TRA	Viewer B Viewer C Viewer B Viewer C Viewer A Viewer B Viewer B Viewer	- + - + - + - - - - - - - - - - - - - -	0 10 0 10 0 10 0 10 0 10 0 10 0 10 0 1	0 13 0 13 0 12 0 12 0 12 0 12 0 12 0 20 0 20 0 0	1 16 2 15 1 17 1 17 1 17 2 8 1 9 1	20 0 20 18 0 18 0 18 0 18 0 19 0 19 0 19 1 18	20 0 20 0 22 0 22 0 22 0 22 0 22 0 21 0 20 0 20	100% (91.2% - 100%) 97.5% (87.1% - 99.6%) 100% (91.2% - 100%) 95% (83.5% - 98.6%) 100% (84.5% - 100%) 97.5% (82% - 100%) 100% (84.5% - 100%) 97.5% (82% - 100%) 100% (84.5% - 100%) 97.5% (82% - 100%) 100% (84.5% - 100%) 97.5% (82% - 100%) 100% (84.5% - 100%) 97.5% (82% - 100%) 100% (84.5% - 100%) 95% (79.5% - 100%) 97.5% (84.5% - 100%) 97.5% (84.5% - 100%) 97.5% (79.5% - 100%)

detected in urine up to 72 hrs. Methylenedioxymethamphetamine (MDMA)

epidurally for epidural anesthesia and analgesia.


cannabis, it is possible to detect its metabolites in human urine.

Synthetic cannabinoids (K2)

Methylenedioxymethamphetamine (ecstasy) is a designer drug first synthesized in 1914 by a German drug dose of the drug, was to produce a clenching of the jaws.

Methamphetamine (MFT/mAMP)

to enhanced stimulation of the central nervous system and induce euphoria, alertness, and a sense of saliva, blood and urine after drinking. increased energy and power. More acute responses produce anxiety, paranoia, psychotic behavior, and cardiac dysrhythmias. The pattern of psychosis which may appear at half-life of about 15 hours and is excreted in urine as amphetamine and oxidized as deaminated and hydroxylated derivatives. However, 40% of methamphetamine is excreted unchanged. Thus the presence of the parent compound in the urine indicates



m a purplish-brown
directly proportional
ess than 20 mg/dL
pecimen dilution.

TRA	Viewer	+	0	0	2	19	21	100% (84.5% - 100%)
(200)	А	-	10	20	8	0	0	95% (79.5% - 100%)
	Viewer	+	0	0	2	19	21	100% (84.5% - 100%)
	В	-	10	20	8	0	0	95% (79.5% - 100%)
	Viewer	+	0	0	1	19	21	100% (84.5% - 100%)
	С	-	10	20	9	0	0	97.5% (82% - 100%)

Precision and Sensitivity

To investigate the precision and sensitivity, each drug sample was analyzed at the following concentrations cutoff -100%, cutoff -75%, cutoff -50%, cutoff -25%, cutoff, cutoff +25%, cutoff +50%, cutoff +75% and the cutoff +100%. All concentrations were confirmed with GC-MS. The study was performed 2 runs /day and lasted 25 days using three different lots of the corresponding drug test. Totally 3 operators participated in the study of the corresponding drug test. Each of the 3 operators tests 2 alignots at each concentration for each lot per day (2 runs/day), for a total of 50 determinations per concentration per lot of the corresponding drug test.

rug Test	Approximate Concentration of	Number of Determinations	N	Results egative/Positi	ve
	Sample (ng/mL)	per Lot	Lot 1	Lot 2	Lot
MP	0	50	50/0	50/0	50/0
00)	75	50	50/0	50/0	50/0
	150	50	50/0	50/0	50/0
	225	50	50/0	50/0	50/0
	300	50	5/45	5/45	4/46
	375	50	0/50	0/50	0/50
	450	50	0/50	0/50	0/50
	525	50	0/50	0/50	0/50
	600	50	0/50	0/50	0/50
MP	0	50	50/0	50/0	50/0
500)	125	50	50/0	50/0	50/0
	250	50	50/0	50/0	50/0
	375	50	50/0	50/0	50/0
	500	50	6/44	7/43	6/44
	625	50	0/50	0/50	0/50
	750	50	0/50	0/50	0/50
	875	50	0/50	0/50	0/50
	1000	50	0/50	0/50	0/50
MP	0	50	50/0	50/0	50/0
000)	250	50	50/0	50/0	50/0
	500	50	50/0	50/0	50/0
	750	50	50/0	50/0	50/0
	1000	50	5/45	6/44	6/44
	1250	50	0/50	0/50	0/50
	1500	50	0/50	0/50	0/50
BAR	1750	50	0/50	0/50	0/50
	2000	50 50	0/50	0/50	0/50
714	0		50/0	50/0	50/0
	75	50 50	50/0	50/0	50/0
	150		50/0	50/0 50/0	50/0 50/0
	225 300	50 50	50/0 5/45	50/0	6/44
	300	50	0/50	5/45 0/50	0/50
	450	50	0/50	0/50	0/50
	525	50	0/50	0/50	0/50
	600	50	0/50	0/50	0/50
P	0	50	50/0	50/0	50/0
	2.5	50	50/0	50/0	50/0
	5.0	50	50/0	50/0	50/0
	7.5	50	50/0	50/0	50/0
	10.0	50	5/45	5/45	6/44
	12.5	50	0/50	0/50	0/50
	15.0	50	0/50	0/50	0/50
	17.5	50	0/50	0/50	0/50
	20.0	50	0/50	0/50	0/50
O (200)	0	50	50/0	50/0	50/0
. /	50	50	50/0	50/0	50/0
	100	50	50/0	50/0	50/0
	150	50	50/0	50/0	50/0
	200	50	4/46	4/46	4/46
	250	50	0/50	0/50	0/50
	300	50	0/50	0/50	0/50
	350	50	0/50	0/50	0/50
	400	50	0/50	0/50	0/50
O (300)	0	50	50/0	50/0	50/0
	75	50	50/0	50/0	50/0
	150	50	50/0	50/0	50/0
	225	50	50/0	50/0	50/0
	300	50	6/44	5/45	6/44
	375	50	0/50	0/50	0/50
	450	50	0/50	0/50	0/50
	525	50	0/50	0/50	0/50
	600	50	0/50	0/50	0/50
C (100)	0	50	50/0	50/0	50/0
	25	50	50/0	50/0	50/0
	50	50	50/0	50/0	50/0
	75	50	50/0	50/0	50/0
	100	50	4/46	4/46	3/47
	125	50	0/50	0/50	0/50
	150	50	0/50	0/50	0/50
	175	50	0/50	0/50	0/50
	200	50	0/50	0/50	0/50
OC (150)	0	50	50/0	50/0	50/0
	37.5	50	50/0	50/0	50/0

Г	112.5	50	50/0	50/0	50
L	150	50	7/43	6/44	7/4
	187.5	50	0/50	0/50	0/5
_	225	50	0/50	0/50	0/5
_	262.5	50	0/50	0/50	0/5
000 1000	300	50	0/50	0/50	0/5
COC (300)	0	50	50/0	50/0	50
-	75	50	50/0	50/0	50
-	150	50	50/0	50/0	50
F	225	50	50/0	50/0	50
-	300	50	6/44	5/45	5/4
-	375	50	0/50	0/50	0/5
-	450	50	0/50	0/50	0/5
	525 600	50 50	0/50	0/50 0/50	0/5
COT (200)	0	50	50/0	50/0	50
	50	50	50/0	50/0	50
F	100	50	50/0	50/0	50
F	150	50	48/2	49/1	47
-	200	50	6/44	4/46	5/4
-	250	50	4/46	3/47	2/4
	300	50	0/50	0/50	0/5
-	350	50	0/50	0/50	0/5
-	400	50	0/50	0/50	0/5
EDDP (100)	0	50	50/0	50/0	50
	25	50	50/0	50/0	50
F	50	50	50/0	50/0	50
F	75	50	48/2	46/4	47
	100	50	6/44	5/45	5/4
	125	50	2/48	3/47	5/4
Γ	150	50	0/50	0/50	0/5
	175	50	0/50	0/50	0/5
	200	50	0/50	0/50	0/5
EDDP (300)	0	50	50/0	50/0	50
	75	50	50/0	50/0	50
L	150	50	50/0	50/0	50
	225	50	50/0	50/0	50
Ļ	300	50	6/44	5/45	6/4
_	375	50	0/50	0/50	0/5
-	450	50	0/50	0/50	0/5
-	525	50	0/50	0/50	0/5
=	600	50	0/50	0/50	0/5
EtG	0	50	50/0	50/0	50
F	125	50	50/0	50/0	50
F	250	50	50/0	50/0	50/
	375	50	50/0	50/0	50
-	500	50	5/45	4/46	5/4
	625	50	0/50	0/50	0/5
-	750	50	0/50	0/50	0/5
-	875 1000	50 50	0/50	0/50 0/50	0/5
FTY(20)	0	50	50/0	50/0	50/5
	5	50	50/0	50/0	50/
F	10	50	50/0	50/0	50
F	15	50	50/0	50/0	50
-	20	50	4/46	5/45	5/4
F	25	50	0/50	0/50	0/5
F	30	50	0/50	0/50	0/5
F	35	50	0/50	0/50	0/5
F	40	50	0/50	0/50	0/5
FTY(100)	0	50	50/0	50/0	50
	25	50	50/0	50/0	50
F	50	50	50/0	50/0	50
F	75	50	50/0	50/0	50
Γ	100	50	3/47	2/48	4/4
	125	50	0/50	0/50	0/5
Γ	150	50	0/50	0/50	0/5
	175	50	0/50	0/50	0/5
	200	50	0/50	0/50	0/5
К2	0	50	50/0	50/0	50
JWH-018	12.5	50	50/0	50/0	50
Pentanoic	25.0	50	50/0	50/0	50
Acid	37.5	50	50/0	50/0	50
	50.0	50	5/45	6/44	5/4
L	62.5	50	0/50	0/50	0/5
	75.0	50	0/50	0/50	0/5
L.	87.5	50	0/50	0/50	0/5
Ē	100.0	50	0/50	0/50	0/5
		50	50/0	50/0	50
К2	0				50
JWH-073	12.5	50	50/0	50/0	
JWH-073 Butanoic			50/0 50/0	50/0 50/0	
JWH-073	12.5	50			50
JWH-073 Butanoic	12.5 25.0	50 50	50/0	50/0	50. 50.
JWH-073 Butanoic	12.5 25.0 37.5	50 50 50	50/0 50/0	50/0 50/0	50, 50, 5/4
JWH-073 Butanoic	12.5 25.0 37.5 50.0	50 50 50 50	50/0 50/0 5/45	50/0 50/0 6/44	50, 50, 50, 5/4 0/5 0/5
JWH-073 Butanoic	12.5 25.0 37.5 50.0 62.5	50 50 50 50 50 50	50/0 50/0 5/45 0/50	50/0 50/0 6/44 0/50	50/ 50/ 5/4 0/5
JWH-073 Butanoic	12.5 25.0 37.5 50.0 62.5 75.0	50 50 50 50 50 50 50	50/0 50/0 5/45 0/50 0/50	50/0 50/0 6/44 0/50 0/50	50, 50, 5/4 0/5 0/5
JWH-073 Butanoic	12.5 25.0 37.5 50.0 62.5 75.0 87.5	50 50 50 50 50 50 50 50	50/0 50/0 5/45 0/50 0/50 0/50	50/0 50/0 6/44 0/50 0/50 0/50	50, 50, 5/4 0/5 0/5 0/5
JWH-073 Butanoic Acid	12.5 25.0 37.5 50.0 62.5 75.0 87.5 100.0	50 50 50 50 50 50 50 50 50	50/0 50/0 5/45 0/50 0/50 0/50 0/50	50/0 50/0 6/44 0/50 0/50 0/50 0/50	50, 50, 5/4 0/5 0/5
JWH-073 Butanoic Acid	12.5 25.0 37.5 50.0 62.5 75.0 87.5 100.0 0	50 50 50 50 50 50 50 50 50 50 50	50/0 50/0 5/45 0/50 0/50 0/50 0/50 50/0	50/0 50/0 6/44 0/50 0/50 0/50 0/50 50/0	50, 50, 5/4 0/5 0/5 0/5 0/5 50
JWH-073 Butanoic Acid	12.5 25.0 37.5 50.0 62.5 75.0 87.5 100.0 0 75	50 50 50 50 50 50 50 50 50 50 50 50	50/0 50/0 5/45 0/50 0/50 0/50 0/50 50/0 50/	50/0 50/0 6/44 0/50 0/50 0/50 0/50 50/0 50/0	50, 50, 5/4 0/5 0/5 0/5 0/5 50

	450	50	0/50	0/50	0/5
	525	50	0/50	0/50	0/5
	600	50	0/50	0/50	0/5
KET (1000)	0	50	50/0	50/0	50/
_	250	50	50/0	50/0	50/
-	500	50	50/0	50/0	50/
	750	50	47/3	48/2	47/
	1000	50	5/45	4/46 2/48	5/4 3/4
-	1250	50	2/48		
-	1500 1750	50 50	0/50	0/50 0/50	0/5
-	2000	50	0/50	0/50	0/5
KRA	0	50	50/0	50/0	50/
	75	50	50/0	50/0	50/
-	150	50	50/0	50/0	50/
-	225	50	50/0	50/0	50/
	300	50	3/47	5/45	4/4
	375	50	0/50	0/50	0/5
_	450	50	0/50	0/50	0/5
	525	50	0/50	0/50	0/5
	600	50	0/50	0/50	0/5
MDMA	0	50	50/0	50/0	50/
	125	50	50/0	50/0	50/
-	250	50	50/0	50/0	50/
-		50	-		
	375		50/0	50/0 6/44	50/ 5/4
	500 625	50	7/43	6/44	5/4
	625	50	0/50	0/50	0/5
	750	50	0/50	0/50	0/5
	875	50	0/50	0/50	0/5
	1000	50	0/50	0/50	0/5
MET	0	50	50/0	50/0	50/
(mAMP)	75	50	50/0	50/0	50/
(300)	150	50	50/0	50/0	50/
L	225	50	50/0	50/0	50/
L	300	50	3/47	5/45	4/4
	375	50	0/50	0/50	0/5
	450	50	0/50	0/50	0/5
	525	50	0/50	0/50	0/5
	600	50	0/50	0/50	0/5
MET	0	50	50/0	50/0	50/
(mAMP)	125	50	50/0	50/0	50/
(500)	250	50	50/0	50/0	50/
	375	50	50/0	50/0	50/
	500	50	5/45	4/46	4/4
	625	50	0/50	0/50	0/5
	750	50	0/50	0/50	0/5
(mAMP) (500) MET (mAMP)	875	50	0/50	0/50	0/5
	1000	50	0/50	0/50	0/5
MET	0	50	50/0	50/0	50/
	250	50	50/0	50/0	50/
(1000)	500	50	50/0	50/0	50/
	750	50	50/0	50/0	50/
	1000	50	5/45	6/44	4/4
	1250	50	0/50	0/50	0/5
	1500	50	0/50	0/50	0/5
	1750	50	0/50	0/50	0/5
	2000	50	0/50	0/50	0/5
MOP/OPI100	0	50	50/0	50/0	50/
			50/0	50/0	
⊢	25 50	50 50	50/0	50/0	50/ 50/
\vdash	75	50	50/0	50/0	50/
			-		
\vdash	100	50	4/46	4/46	5/4
	125	50	0/50	0/50	0/5
	150	50	0/50	0/50	0/5
	175	50	0/50	0/50	0/5
	200	50	0/50	0/50	0/5
	0	50	50/0	50/0	50/
MOP/OPI300	35			- E0/0	50/
MOP/OPI300	75	50	50/0	50/0	-
MOP/OPI300	150	50 50	50/0 50/0	50/0	
MOP/OPI300	150 225	50 50 50	50/0 50/0 50/0	50/0 50/0	50/
MOP/OPI300	150 225 300	50 50 50 50	50/0 50/0 50/0 7/43	50/0 50/0 5/45	50/ 6/4
MOP/OPI300	150 225 300 375	50 50 50 50 50 50	50/0 50/0 50/0 7/43 0/50	50/0 50/0 5/45 0/50	50/ 6/4- 0/5
MOP/OPI300	150 225 300 375 450	50 50 50 50 50 50 50	50/0 50/0 50/0 7/43 0/50 0/50	50/0 50/0 5/45 0/50 0/50	50/0 6/4- 0/50 0/50
MOP/OPI300	150 225 300 375 450 525	50 50 50 50 50 50 50 50	50/0 50/0 50/0 7/43 0/50 0/50 0/50	50/0 50/0 5/45 0/50 0/50 0/50	50/0 6/44 0/50 0/50
	150 225 300 375 450 525 600	50 50 50 50 50 50 50 50 50	50/0 50/0 50/0 7/43 0/50 0/50 0/50 0/50	50/0 50/0 5/45 0/50 0/50 0/50 0/50	50/0 6/4- 0/50 0/50 0/50
	150 225 300 375 450 525 600 0	50 50 50 50 50 50 50 50 50 50 50	50/0 50/0 50/0 7/43 0/50 0/50 0/50 0/50 0/50 50/0	50/0 50/0 5/45 0/50 0/50 0/50 0/50 50/0	50/0 6/4- 0/50 0/50 0/50 50/
	150 225 300 375 450 525 600 0 50	50 50 50 50 50 50 50 50 50 50 50 50	50/0 50/0 50/0 7/43 0/50 0/50 0/50 0/50	50/0 50/0 5/45 0/50 0/50 0/50 0/50	50/0 6/4- 0/50 0/50 0/50 50/
	150 225 300 375 450 525 600 0	50 50 50 50 50 50 50 50 50 50 50	50/0 50/0 50/0 7/43 0/50 0/50 0/50 0/50 0/50 50/0	50/0 50/0 5/45 0/50 0/50 0/50 0/50 50/0	50/0 6/4- 0/50 0/50 0/50 50/ 50/
MOP/OPI300	150 225 300 375 450 525 600 0 50	50 50 50 50 50 50 50 50 50 50 50 50	50/0 50/0 50/0 7/43 0/50 0/50 0/50 0/50 50/0 50/0 50/0 50/0 50/0	50/0 50/0 5/45 0/50 0/50 0/50 0/50 50/0 50/	50// 6/4/ 0/5/ 0/5/ 0/5/ 50/ 50/
	150 225 300 375 450 525 600 0 50 50 100	50 50 50 50 50 50 50 50 50 50 50 50 50 5	50/0 50/0 50/0 7/43 0/50 0/50 0/50 0/50 50/0 50/0 50/0 50/0 50/0 50/0 50/0	50/0 50/0 5/45 0/50 0/50 0/50 0/50 50/0 50/	50// 6/44 0/50 0/50 0/50 50/ 50/ 50/
	150 225 300 375 450 525 600 0 50 50 100 150	50 50 50 50 50 50 50 50 50 50 50 50 50 5	50/0 50/0 50/0 7/43 0/50 0/50 0/50 0/50 50/0 50/0 50/0 50/0 50/0 50/0 50/0 50/0	50/0 50/0 5/45 0/50 0/50 0/50 0/50 0/50	50// 6/44 0/55 0/55 0/55 50/ 50/ 50/ 50/ 4/4
	150 225 300 375 450 525 600 0 50 50 100 150 200	50 50 50 50 50 50 50 50 50 50 50 50 50 5	50/0 50/0 50/0 7/43 0/50 0/50 0/50 0/50 50/0 50/0 50/0 50/0 50/0 50/0 50/0 50/0 50/0 50/0 50/0 50/0 50/0 50/0 50/0	50/0 50/0 5/45 0/50 0/50 0/50 0/50 50/0 50/	50// 6/44 0/50 0/50 50/ 50/ 50/ 50/ 50/ 4/4
	150 225 300 375 450 525 600 0 50 50 100 150 200 250	50 50 50 50 50 50 50 50 50 50 50 50 50 5	50/0 50/0 50/0 7/43 0/50 0/50 0/50 0/50 50/0	50/0 50/0 5/45 0/50 0/50 0/50 0/50 50/0 50/	50// 6/44 0/50 0/50 50/ 50/ 50/ 50/ 50/ 50/ 50/ 5
	150 225 300 375 450 525 600 0 50 50 100 150 200 250 300	50 50 50 50 50 50 50 50 50 50 50 50 50 5	50/0 50/0 50/0 7/43 0/50 0/50 0/50 0/50 50/0	50/0 50/0 5/45 0/50 0/50 0/50 0/50 50/0 50/	50// 6/44 0/55 0/55 50/ 50/ 50/ 50/ 50/ 4/4 0/5 0/5 0/5
MTD (200)	150 225 300 375 450 525 600 0 50 50 100 150 200 250 300 350 400	50 50 50 50 50 50 50 50 50 50 50 50 50 5	50/0 50/0 50/0 7/43 0/50 0/50 0/50 50/0 0/50 0/50 0/50	50/0 50/0 5/45 0/50 0/50 0/50 50/0 50/0	50// 6/44 0/55 0/55 50/ 50/ 50/ 50/ 50/ 4/4 0/5 0/5 0/5 0/5
	150 225 300 375 450 525 600 0 50 50 100 150 200 250 300 350	50 50 50 50 50 50 50 50 50 50 50 50 50 5	50/0 50/0 50/0 7/43 0/50 0/50 0/50 0/50 50/0	50/0 50/0 5/45 0/50 0/50 0/50 50/0 50/0	50// 6/44 0/55 0/55 50/ 50/ 50/ 50/ 50/ 50/ 50/ 5
MTD (200)	150 225 300 375 450 525 600 0 50 50 100 150 200 250 300 350 350 400 0 75	50 50 50 50 50 50 50 50 50 50 50 50 50 5	50/0 50/0 50/0 7/43 0/50 0/50 0/50 50/0 50/0 50/0 50/0 50/0 50/0 50/0 50/0 50/0 0/50 0/50 0/50 0/50 0/50 0/50 0/50 50/0 50/0 50/0	50/0 50/0 5/45 0/50 0/50 0/50 50/0 50/0	50// 6/44 0/55 0/55 50/ 50/ 50/ 50/ 50/ 50/ 50/ 5
MTD (200)	150 225 300 375 450 525 600 0 50 50 100 150 250 250 300 350 400 0 75 150	50 50	50/0 50/0 50/0 50/0 7/43 0/50 0/50 0/50 50/0 50/0 50/0 50/0 50/0 50/0 50/0 50/0 5/45 0/50 0/50 0/50 0/50 50/0 50/0 50/0 50/0 50/0 50/0 50/0	50/0 50/0 5/45 0/50 0/50 0/50 50/0 50/0	50// 6/44 0/50 0/55 0/55 0/5 50/ 50/ 50/ 50/ 50/
MTD (200)	150 225 300 375 450 525 600 0 50 50 100 150 250 250 300 350 400 0 75 150 225	50 50 50 50 50 50 50 50 50 50 50 50 50 5	50/0 50/0 50/0 7/43 0/50 0/50 0/50 50/0 50/0 50/0 50/0 50/0 50/0 50/0 50/0 50/0 50/0 50/50 0/50 0/50 0/50 50/0 50/0 50/0 50/0 50/0 50/0 50/0 50/0 50/0 50/0 50/0 50/0	50/0 50/0 5/45 0/50 0/50 0/50 50/0 50/0	50// 6/44 0/50 0/55 0/55 50/ 50/ 50/ 50/ 50/ 50/
MTD (200)	150 225 300 375 450 525 600 0 0 50 100 150 200 250 300 350 400 0 75 150 225 300	50 50	50/0 50/0 50/0 7/43 0/50 0/50 0/50 50/0 50/0 50/0 50/0 50/0 50/0 50/0 50/0 50/0 50/0 0/50 0/50 0/50 0/50 50/0	50/0 50/0 5/45 0/50 0/50 0/50 50/0 50/0	50// 6/44 0/50 0/55 50// 50// 50// 50// 50// 5
MTD (200)	150 225 300 375 450 525 600 0 50 100 150 200 250 300 350 400 0 75 150 225 300 375	50 50	50/0 50/0 50/0 7/43 0/50 0/50 0/50 50/0 50/0 0/50 50/0 50/0 50/0 50/0 50/0 50/0 50/0 50/0 0/50 0/50 0/50 50/0	50/0 50/0 5/45 0/50 0/50 0/50 50/0 50/0	50// 50// 6/44 0/50 0/55 0/55 0/5 50// 50// 50// 50
MTD (200)	150 225 300 375 450 525 600 0 0 50 100 150 200 250 300 350 400 0 75 150 225 300	50 50	50/0 50/0 50/0 7/43 0/50 0/50 0/50 50/0 50/0 50/0 50/0 50/0 50/0 50/0 50/0 50/0 50/0 0/50 0/50 0/50 0/50 50/0	50/0 50/0 5/45 0/50 0/50 0/50 50/0 50/0	50// 6/44 0/50 0/55 50// 50// 50// 50// 50// 5

OPI	0	50	50/0	50/0	50
	500	50	50/0	50/0	50
	1000	50	50/0	50/0	50
	1500	50	50/0	50/0	50
	2000	50	5/45	5/45	6/4
	2500	50	0/50	0/50	0/
	3000	50	0/50	0/50	0/
	3500	50	0/50	0/50	0/
	4000	50	0/50	0/50	0/
OXY	0	50	50/0	50/0	50
	25	50	50/0	50/0	50
	50	50	50/0	50/0	50
	75	50	50/0	50/0	50
	100	50	4/46	4/46	5/
	125	50	0/50	0/50	0/
	150	50	0/50	0/50	0/
	175	50	0/50	0/50	0/:
	200	50	0/50	0/50	0/
PCP	0	50	50/0	50/0	50
	6.25	50	50/0	50/0	50
	12.5	50	50/0	50/0	50
	18.75	50	50/0	50/0	50
	25	50	6/44	4/46	5/-
	31.25	50	0/50	0/50	0/
		50			
	37.5		0/50	0/50	0/
	43.75	50	0/50	0/50	0/
	50	50	0/50	0/50	0/5
PPX	0	50	50/0	50/0	50
	75	50	50/0	50/0	50
				1	
	150	50	50/0	50/0	50
	225	50	50/0	50/0	50
	300	50	6/44	5/45	5/-
	375	50	0/50	0/50	0/
	450	50	0/50	0/50	0/
	525	50	0/50	0/50	0/
	600	50	0/50	0/50	0/
TCA	0	50	50/0	50/0	50
	250	50	50/0	50/0	50
	500	50	50/0	50/0	50
	750	50	50/0	50/0	50
	1000	50	6/44	5/45	4/-
	1250	50	0/50	0/50	0/5
	1500	50	0/50	0/50	0/!
	1750	50	0/50	0/50	0/
	2000	50	0/50	0/50	0/
THC (25)	0	50	50/0	50/0	50
	6.25	50	50/0	50/0	50
	12.5	50	50/0	50/0	50
	18.75	50	50/0	48/2	47
	25	50	5/45	5/45	3/-
	31.25	50	2/48	3/47	1/-
	37.5	50	0/50	0/50	0/
	43.75	50	0/50	0/50	0/
	50	50	0/50	0/50	0/:
THC (40)	0	50	50/0	50/0	50
	10	50	50/0	50/0	50
	20	50	50/0	50/0	50
				1	
	30	50	50/0	50/0	50
	40	50	5/45	5/45	3/
	50	50	0/50	0/50	0/
	60	50	0/50	0/50	0/
	70				
		50	0/50	0/50	0/
	80	50	0/50	0/50	0/
THC (50)	0	50	50/0	50/0	50
	12.5	50	50/0	50/0	50
	25.0	50	50/0	50/0	50
	37.5	50	50/0	50/0	50
	50.0	50	4/46	4/46	5/-
	62.5	50	0/50	0/50	0/
	75.0	50	0/50	0/50	0/
	87.5	50	0/50	0/50	0/
	100.0	50	0/50	0/50	0/
		50	0,00	50/0	50
TRA (100)	0	50	50/0	50/0	
TRA (100)	0	50	50/0	1 1	50
TRA (100)	0 25	50 50	50/0 50/0	50/0	
TRA (100)	0 25 50	50 50 50	50/0 50/0 50/0	50/0 50/0	50
TRA (100)	0 25 50 75	50 50 50 50	50/0 50/0 50/0 48/2	50/0	50 47
TRA (100)	0 25 50	50 50 50	50/0 50/0 50/0	50/0 50/0	50 47
TRA (100)	0 25 50 75 100	50 50 50 50 50 50	50/0 50/0 50/0 48/2 4/46	50/0 50/0 49/1 5/45	50 47 5/-
TRA (100)	0 25 50 75 100 125	50 50 50 50 50 50 50	50/0 50/0 48/2 4/46 1/49	50/0 50/0 49/1 5/45 4/46	50 47 5/- 3/-
TRA (100)	0 25 50 75 100 125 150	50 50 50 50 50 50 50 50	50/0 50/0 50/0 48/2 4/46 1/49 0/50	50/0 50/0 49/1 5/45 4/46 0/50	50 47 5/- 3/- 0/-
TRA (100)	0 25 50 75 100 125 150 175	50 50 50 50 50 50 50	50/0 50/0 48/2 4/46 1/49	50/0 50/0 49/1 5/45 4/46	50 47 5/- 3/- 0/-
TRA (100)	0 25 50 75 100 125 150	50 50 50 50 50 50 50 50	50/0 50/0 50/0 48/2 4/46 1/49 0/50	50/0 50/0 49/1 5/45 4/46 0/50	50 47 5/- 3/- 0/-
	0 25 50 75 100 125 150 175 200	50 50 50 50 50 50 50 50 50 50	50/0 50/0 50/0 48/2 4/46 1/49 0/50 0/50 0/50	50/0 50/0 49/1 5/45 4/46 0/50 0/50 0/50	50 47 5/- 3/- 0/- 0/-
TRA (100) TRA (200)	0 25 50 75 100 125 150 175 200 0	50 50 50 50 50 50 50 50 50 50 50	50/0 50/0 50/0 48/2 4/46 1/49 0/50 0/50 0/50 50/0	50/0 50/0 49/1 5/45 4/46 0/50 0/50 0/50 50/0	50 47 5/- 3/- 0/- 0/- 0/- 0/- 50
	0 25 50 75 100 125 150 175 200 0 50	50 50 50 50 50 50 50 50 50 50 50 50 50	50/0 50/0 50/0 48/2 4/46 1/49 0/50 0/50 0/50 50/0 50/0	50/0 50/0 49/1 5/45 4/46 0/50 0/50 0/50 50/0 50/0	50 47 5/, 0/, 0/, 0/, 0/, 0/, 50 50
	0 25 50 75 100 125 150 175 200 0 50 50 100	50 50 50 50 50 50 50 50 50 50 50 50 50 5	50/0 50/0 50/0 48/2 4/46 1/49 0/50 0/50 0/50 50/0 50/0 50/0	50/0 50/0 49/1 5/45 4/46 0/50 0/50 0/50 0/50 50/0 50/0 50/0	50 47 5/- 3/- 0/- 0/- 50 50 50
	0 25 50 75 100 125 150 175 200 0 50	50 50 50 50 50 50 50 50 50 50 50 50 50	50/0 50/0 50/0 48/2 4/46 1/49 0/50 0/50 0/50 50/0 50/0	50/0 50/0 49/1 5/45 4/46 0/50 0/50 0/50 50/0 50/0	50 47 5/- 3/- 0/- 0/- 50 50 50
	0 25 50 75 100 125 150 175 200 0 50 50 100 150	50 50 50 50 50 50 50 50 50 50 50 50 50 5	50/0 50/0 50/0 48/2 4/46 1/49 0/50 0/50 0/50 50/0 50/0 50/0 50/0	50/0 50/0 49/1 5/45 4/46 0/50 0/50 0/50 50/0 50/0 50/0 50/0 50/	50 47 5/- 3/- 0/- 0/- 50 50 50 50
	0 25 50 75 100 125 150 175 200 0 50 50 100 150 200	50 50 50 50 50 50 50 50 50 50 50 50 50 5	50/0 50/0 50/0 40/0 4/46 1/49 0/50 0/50 50/0 50/0 50/0 50/0 50/0 50/0 50/0 50/0 50/0 50/0 50/0 4/46	50/0 50/0 49/1 5/45 4/46 0/50 0/50 0/50 50/0 50/0 50/0 50/0 50/	50 47 5/- 3/- 0/- 0/- 50 50 50 50 50 5/-
	0 25 50 75 100 125 150 175 200 0 50 50 100 150 200 250	50 50 50 50 50 50 50 50 50 50 50 50 50 5	50/0 50/0 50/0 48/2 4/46 1/49 0/50 0/50 50/0	50/0 50/0 49/1 5/45 4/46 0/50 0/50 0/50 50/0 50/0 50/0 50/0 6/44 0/50	50 47 5/4 0/5 0/5 0/5 50 50 50 50 50 50
	0 25 50 75 100 125 150 175 200 0 50 50 100 150 200	50 50 50 50 50 50 50 50 50 50 50 50 50 5	50/0 50/0 50/0 40/0 4/46 1/49 0/50 0/50 50/0 50/0 50/0 50/0 50/0 50/0 50/0 50/0 50/0 50/0 50/0 4/46	50/0 50/0 49/1 5/45 4/46 0/50 0/50 0/50 50/0 50/0 50/0 50/0 50/	50 50 47 5/4 0/5 0/5 50 50 50 50 50 50 50 50 50 50 50 50 50
	0 25 50 75 100 125 150 175 200 0 50 50 100 150 200 250	50 50 50 50 50 50 50 50 50 50 50 50 50 5	50/0 50/0 50/0 48/2 4/46 1/49 0/50 0/50 50/0	50/0 50/0 49/1 5/45 4/46 0/50 0/50 0/50 50/0 50/0 50/0 50/0 6/44 0/50	50 47 5/- 3/- 0/- 50 50 50 50 50 50 50 50

Specificity and Cross Reactivity

To test the specificity of the test, the test device was used to test various drugs, drug metabolites and other components of the same class that are likely to be present in urine. All the components were added to drugfree normal human urine. The following structurally related compounds produced positive results with the test

Concentration
(ng/mL)
1,000
12,500 25,000
25,000
300
600 tamine
lamme
mine 500
nine 3,000
nine 300
300
40,000
8,000
20,000
8,000
mine 800
10,000
3,000
500
25,000
37,500
10,000
25,000
500
10,000
mine 500
(MDA) 500
mine 1,000
25,000
5,000
75,000
15,000
25,000
50,000
50,000
50,000 100,000 1,000
50,000
50,000 100,000 1,000 50,000
50,000 100,000 1,000 50,000
50,000 100,000 1,000 50,000 50,000
50,000 100,000 1,000 50,000 50,000 50,000
50,000 100,000 1,000 50,000 50,000 50,000 25,000 25,000 mine(2,000
50,000 100,000 1,000 50,000 50,000 50,000 25,000 mine(2,000 50,000
50,000 100,000 1,000 50,000 50,000 50,000 25,000 25,000 mine(2,000
50,000 100,000 1,000 50,000 50,000 50,000 25,000 mine(2,000 50,000
50,000 100,000 1,000 50,000 50,000 50,000 25,000 25,000 mine(2,000 10,000
50,000 100,000 1,000 50,000 50,000 25,000 25,000 mine(2,000 10,000 100
50,000 100,000 1,000 50,000 50,000 25,000 25,000 mine(2,000 10,000 100 100
50,000 100,000 1,000 50,000 50,000 25,000 25,000 mine(2,000 10,000 100 100 200
50,000 100,000 1,000 50,000 50,000 25,000 25,000 mine(2,000 50,000 10,000 100 100 100 400

Buprenorphine	10	Morphine 3-β-D-glucuronide	200
Buprenorphine -3-D-Glucuronide	15	Norcodeine	500
Norbuprenorphine	20	Normorphine	5,000
Norbuprenorphine 3-D-Glucuronide	200	Oxycodone	1000
Benzodiazepines (BZO200)		Oxymorphone	10,000
Oxazepam	200	Procaine	100,000
Alprazolam	50	Thebaine	5,000
a-Hydroxyalprazolam	500	Morphine (MOP/OPI300)	
Bromazepam	500	Morphine	300
Chlordiazepoxide	800	Codeine	300
Clobazam	50	Ethyl Morphine	300
Clonazepam	700	Heroin	300
Clorazepate dipotassium	50	Hydrocodone	5,000
Desalkylflurazepam	200	Hydromorphone	5,000
Diazepam	50	Morphine-3-β-d-glucuronide	1,000
Estazolam	1,000	6-MonoacetyImorphine	400
Flunitrazepam	200	Normorphine	10,000
D,L-Lorazepam	800	Oxycodone	25,000
Midazolam	5,000	Oxymorphone	10,000
Nitrazepam	50	Thebaine	30,000
Norchlordiazepoxide	100	Methadone (MTD200)	
Nordiazepam	200	Methadone	200
Temazepam	50	Doxylamine	40,000
Triazolam	500	Methadone (MTD300)	
Benzodiazepines (BZO300)		Methadone	300
Oxazepam	300	Doxylamine	50,000
Alprazolam	200	Opiate (OPI)	00,000
a-Hydroxyalprazolam	1,500	Morphine	2.000
	1,500	Codeine	2,000
Bromazepam Chlordiazepoxide	1,500	Ethyl Morphine	2,000 5,000
	1,500		2,000
Clobazam Clonazepam	800	Heroin Hydrocodone	12,000
Clorazepate dipotassium	200	Hydromorphone	5,000
Desalkylflurazepam	400	Levorphanol	75,000
Diazepam	200	6-MonoacetyImorphine	5,000
Estazolam	2,500	Morphine 3-β-D-glucuronide	2,000
Flunitrazepam	400	Norcodeine	12,500
D,L-Lorazepam	1500	Normorphine	50,000
Midazolam	12,500	Oxycodone	25,000
Nitrazepam	100	Oxymorphone	25,000
Norchlordiazepoxide	200	Procaine	150,000
Nordiazepam	400	Thebaine	100,000
Temazepam	100	Oxycodone (OXY)	
Triazolam	2,500	Oxycodone	100
Cocaine (COC100)		Dihydrocodeine	20,000
Benzoylecgonine	100	Codeine	100,000
Cocaine	250	Hydromorphone	100,000
Cocaethylene	4,000	Morphine	>100,00
Ecgonine	10,000	Acetylmorphine	>100,00
Cocaine (COC150)		Buprenorphine	>100,00
Benzoylecgonine	150	Ethylmorphine	>100,00
Cocaine	375	Phencyclidine (PCP)	
Cocaethylene	6,250	Phencyclidine	25
Ecgonine	16,000	4-Hydroxyphencyclidine	12,500
Norcocaine	50,000	Propoxyphene (PPX)	
Cocaine (COC300)		d-Propoxyphene	300
Benzoylecgonine	300	d-Norpropoxyphene	300
Cocaine	750	Nortriptyline (TCA)	
Cocaethylene	12,500	Nortriptyline	1,000
Ecgonine	32,000	Nordoxepin	1,000
Cotinine (COT)		Trimipramine	3,000
Cotinine	200	Amitriptyline	1,500
EDDP100		Promazine	1,500
2-ethylidene-1,5-dimethyl-3,3-	100	Decimeration	200
diphenylpyrrolidine	100	Desipramine	200
Methadone	100,000	Imipramine	400
EMDP	100,000	Clomipramine	12,500
EDDP300		Doxepin	2,000
2-ethylidene-1,5-dimethyl-3,3-	300	Maprotiling	2 000
diphenylpyrrolidine	300	Maprotiline	2,000
Methadone	300,000	Promethazine	25,000
EMDP	300,000	Cannabinoids (THC25)	
Ethyl Glucuronide (EtG)		11-nor-∆9-THC-9-COOH	25
Ethyl Glucuronide	500	11-nor-∆8-THC-9-COOH	15
Fentanyl (FTY20)		11-hydroxy-∆9-Tetrahydrocannabino	
Norfentanyl	20	Δ8-Tetrahydrocannabinol	3,750
Fentanyl	100	Δ9-Tetrahydrocannabinol	5,000
Fentanyl (FTY100)		Cannabinol	50,000
Fentanyl	100	Cannabidiol	50,000
Norfentanyl	>100,000	Cannabinoids (THC40)	20,000
Synthetic Cannabinoids (K2)	- 100,000	11-nor-Δ9-THC-9-COOH	40
JWH-018 Pentanoic Acid	50	11-nor-Δ9-THC-9-COOH 11-nor-Δ8-THC-9-COOH	40 20
JWH-018 Pentanoic Acid JWH-073 Butanoic Acid			
	50	11-hydroxy-Δ9-Tetrahydrocannabino	
JWH-018 N-4-hydroxypentyl	2,000	Δ8-Tetrahydrocannabinol	6,000
JWH-018 (Spice Cannabinoid)	1,000	Δ9-Tetrahydrocannabinol	8,000
JWH-018 4-Hydroxypentyl metabolite	^{∋-} 1,000	Cannabinol	80,000
D5 (indole-D5)			
JWH-073 (Spice Cannabinoid)	2,000	Cannabidiol	80,000
JWH-073 3-Hydroxybutyl metabolite	1,000	Cannabinoids (THC50)	
JWH-073 3-Hydroxybutyl metabolite-D	⁰⁵ 1,000	11-nor-∆9-THC-9-COOH	50
	a share		~ ~
(indole-D5)	.,		
	1,000	11-nor-Δ8-THC-9-COOH	30

	200
	500
	5,000
	1000 10,000
	100,000
	5,000
	300
	300
	300
	300
	5,000
	5,000 1,000
	400
	10,000
	25,000
	10,000
	30,000
	200
	40,000
	300
	50,000
	2,000
	2,000
	5,000
	2,000
	12,500 5,000
	5,000 75,000
	5,000
	2,000
	12,500
	50,000
	25,000
	25,000
	150,000 100,000
	100,000
	100
	20,000
	100,000
	100,000 100,000
	100,000 100,000 >100,000
	100,000 100,000 >100,000 >100,000
	100,000 100,000 >100,000
	100,000 100,000 >100,000 >100,000 >100,000
	100,000 100,000 >100,000 >100,000 >100,000 >100,000 25
	100,000 100,000 >100,000 >100,000 >100,000 >100,000
	100,000 100,000 > 100,000 > 100,000 > 100,000 > 100,000 25 12,500
	100,000 100,000 >100,000 >100,000 >100,000 >100,000 25 12,500 300
	100,000 100,000 > 100,000 > 100,000 > 100,000 > 100,000 25 12,500
	100,000 100,000 > 100,000 > 100,000 > 100,000 > 100,000 2 5 12,500 300 300
	100,000 100,000 >100,000 >100,000 >100,000 >100,000 25 12,500 300
	100,000 100,000 > 100,000 > 100,000 > 100,000 200 100,000 125 12,500 300 300 300 1,000 1,000 3,000
	100,000 100,000 > 100,000 > 100,000 > 100,000 2 5 12,500 300 300 1,000 1,000 1,500
	100,000 100,000 > 100,000 > 100,000 > 100,000 25 12,500 300 300 1,000 1,000 3,000
	100,000 100,000 > 100,000 > 100,000 > 100,000 2 5 12,500 300 300 1,000 1,000 1,500
	100,000 100,000 >100,000 >100,000 >100,000 >100,000 25 12,500 300 300 1,000 1,000 1,500 200
	100,000 100,000 > 100,000 > 100,000 > 100,000 > 100,000 2 5 12,500 300 300 1,000 1,000 1,500 1,500
	100,000 100,000 >100,000 >100,000 >100,000 200,000 25 12,500 300 300 1,000 1,000 1,500 1,500 200 400
	100,000 100,000 >100,000 >100,000 >100,000 25 12,500 300 300 300 1,000 1,000 1,500 1,500 200 400 12,500 2,000
	100,000 100,000 > 100,000 > 100,000 > 100,000 > 100,000 2 00 12,500 300 300 1,000 1,000 1,500 1,500 200 400 12,500 2,000 2,000
	100,000 100,000 >100,000 >100,000 >100,000 25 12,500 300 300 300 1,000 1,000 1,500 1,500 200 400 12,500 2,000
	100,000 100,000 >100,000 >100,000 >100,000 200 25 12,500 300 300 300 1,000 1,000 1,000 1,500 1,500 200 400 12,500 2,000 2,000 25,000
	100,000 100,000 > 100,000 > 100,000 > 100,000 > 100,000 2 00 12,500 300 300 1,000 1,000 1,500 1,500 200 400 12,500 2,000 2,000
nnabinol	100,000 100,000 >100,000 >100,000 >100,000 >100,000 25 12,500 300 300 300 1,000 1,000 1,500 1,500 200 400 12,500 2,000 25,000 25
nnabinol	100,000 100,000 >100,000 >100,000 >100,000 >100,000 25 12,500 300 300 300 1,000 1,000 1,500 1,500 200 400 12,500 2,000 2,000 25,000 25 15 1,250 25 15 1,250 20 25 25 25 25 25 25 25 25 25 25
nabinol	100,000 100,000 > 100,000 > 100,000 > 100,000 > 100,000 2 100,000 2 5 12,500 300 300 1,000 1,000 1,500 1,500 2,000 2,000 25,000 25 15 1,250 3,750 5,000
nnabinol	100,000 100,000 > 100,000 > 100,000 > 100,000 > 100,000 2 100,000 2 5 12,500 300 300 1,000 1,000 1,000 1,500 200 400 1,500 2,000 2,000 25,000 25,000 5,000 5,000 5,000
nabinol	100,000 100,000 > 100,000 > 100,000 > 100,000 > 100,000 2 100,000 2 5 12,500 300 300 1,000 1,000 1,500 1,500 2,000 2,000 25,000 25 15 1,250 3,750 5,000
nabinol	100,000 100,000 > 100,000 > 100,000 > 100,000 > 100,000 2 100,000 2 5 12,500 300 300 1,000 1,000 1,000 1,500 200 400 1,500 2,000 2,000 25,000 25,000 5,000 5,000 5,000
nabinol	100,000 100,000 > 100,000 > 100,000 > 100,000 > 100,000 2 5 12,500 300 300 1,000 1,000 1,000 1,500 200 400 1,500 2,000 25,000 25,000 25,000 50,000 50,000 50,000
	100,000 100,000 >100,000 >100,000 >100,000 >100,000 200 25 12,500 300 300 300 300 1,000 1,000 1,500 1,500 200 400 12,500 2,000 25,000 25,000 25,000 25,000 25,000 50,000 5
nabinol	100,000 100,000 >100,000 >100,000 >100,000 >100,000 200 25 12,500 1,000 1,000 1,000 1,500 1,500 1,500 2,000 2,000 25,000 25,000 25,000 25,000 25,000 50,000 50,000 40 20 2,000 20 2,00
	100,000 100,000 >100,000 >100,000 >100,000 >100,000 25 12,500 300 300 300 300 1,000 1,000 1,000 1,500 200 400 12,500 2,000 25,000 25,000 25,000 25,000 25,000 25,000 25,000 25,000 25,000 25,000 20,000 20,000 50,000
	100,000 100,000 >100,000 >100,000 >100,000 >100,000 200 25 12,500 1,000 1,000 1,000 1,500 1,500 1,500 2,000 2,000 25,000 25,000 25,000 25,000 25,000 25,000 25,000 25,000 25,000 200 200 200 200 200 200 200
	100,000 100,000 >100,000 >100,000 >100,000 >100,000 25 12,500 300 300 300 300 1,000 1,000 1,000 1,500 200 400 12,500 2,000 25,000 25,000 25,000 25,000 25,000 25,000 25,000 25,000 25,000 25,000 20,000 20,000 50,000

JWH-210 5-Hydroxypentyl metabolite	5,000	∆8-Tetrahydrocannabinol	7,500
AM2201 4-Hydroxypentyl metabolite	1,000	∆9-Tetrahydrocannabinol	10,000
Ketamine (KET300)		Cannabinol	100,000
Ketamine	300	Cannabidiol	100,000
Methadone	15,000	Tramadol (TRA100)	
Pethidine	3,750	Tramadol	100
Methylamphetamine	3,750	Tramadol (TRA200)	
Methoxyphenamine	3,750	Tramadol	200
Promethazine	7,500		
Phencyclidine	7,500		
Methadone	50,000		
Pethidine	12,500		
Methylamphetamine	12,500		

Effect of Urinary Specific Gravity

The results demonstrate that the urinary specific gravity range of 1.000~1.035 does not affect the test results.

Effect of Urinary pH

The results demonstrate that the range of urinary pH from 4 to 9 does not interfere with the performance of test.

Interfering Substances

Urine specimens may contain substances that could potentially interfere with the test. The following compounds were added to drug-free urine, urine with a drug concentration 25% below the cutoff, and urine with a drug concentration 25% above the cutoff for the corresponding drug test. All potential interferents were added at a concentration of 100 µg/mL. None of the urine samples tested showed any deviation from the expected results.

Acetaminopher Acetophenetidin Acetylsalicylic Acid Aminopyrine Amoxicillin Ampicillin Apomorphine Aspartame Aspirin Atropine Diphenhydramin Benzilic Acid Benzoic Acid Bilirubin Captopril Chloralhydrate Chloramphenico Chlorothiazide Chlorpromazine Chloroquine Cholesterol Clarithromycin Clonidine Cotinine Cortisone Deoxycorticosteror Dextromethorphar Diclofenac Diflunisal

Estrogen Fenoprofen Furosemide Gentisic Acid Hydrochlorothiazide 3-Hvdroxvtvramine Hydrocortisone Isoxsuprine Ketoprofen Labetalol Lamotrigine Levonorgestre Meperidine Meprobamate Nalidixic Acid Naproxen Niacinamide Nifedipine Nitroglycerin Norethindrone 5- Hydroxytyramine Sulfamethazine Sulinda Tetrahydrozoline Thiamine Thioridazine Thioridazine Diphenhydramine D I -Octopamine

DL-Propranolol DL-Tyrosine D-Pseudoephedrine Noscapine O-Hydroxyhippuric Acid Omenrazole Oxalic Acid Oxolinic Acid Oxymetazoline Papaverine Penicillin V Potassiun Penicillin-G Perphenazine Pethidine HCI Phenelzine Prednisone Propranolol HC Quinine Ranitidine Ranitidine HCI Salicylic Acid Triamterene Uric Acid Venlafaxine HC Verapamil Sertraline Zomepirac

Hawwks RL, CN Chiang. Urine Testing for drugs of Abuse. National Institute for Drug Abuse (NIDA), Research Monography 73, 1986

Hofmann F.E., A Handbook on Drug and Alcohol Abuse: The Biomedical Aspects, New York, Oxford University Press, 1983.

McBay, A. J. Clin. Chem. 33,33B-40B, 1987.

ADDITIONAL INFORMATION AND RESOURCES

The following list of organizations may be helpful to you for counseling support and resources. These groups also have an Internet address which can be accessed for additional information. National Clearinghouse for Alcohol and Drug Information www.health.org 1-800-729-6686 Center for Substance Abuse Treatment www.health.org 1-800-662-HELP The National Council on Alcoholism and Drug Dependence www.ncadd.org 1-800-NCA-CALL American Council for Drug Education (ACDE) www.acde.org 1-800-488-DRUG

INDEX OF SYMBOLS



^{30°C} Store between 4°C - 30°C (39°F - 86°F)

Keep drv

Do not re-use

Instruction for Use

Manufactured by Guangzhou Wondfo Biotech Co., LTD Guangzhou, Guangdong, China 510663

Made in China

Rev. A1 Rel.: 2021/09/27

ALCOHOL TEST:

Sensitivity

It is designed for detection of alcohol in urine at the detection sensitivity of 40 mg/dL (0.04 g/dL)

Interference

The following substances were added to samples which had alcohol levels of 0 and 0.08%. None of the substances at the concentrations tested interfered in the Alcohol Tests.

Acetaminophen	20 mg/dL
Caffeine	20 mg/dL
Glucose	2,000 mg/dL
Hemoglobin	1 mg/dL
Human Serum Protein	2,000 mg/dL

The following substances may interfere with the Alcohol Test:

Strong oxidizers	Ascorbic acid
Tannic acid	Polyphenolic compounds
Mercaptans	Uric acid
Bilirubin	Oxalic acid

These compounds are not normally present in sufficient amounts in urine to interfere with the test.

ASSISTANCE

If you have any question regarding to the use of this product, please call our Toll Free Number 1-888-444-3657 (9:30 a.m. to 5:00 p.m. CDT M-F).

BIBLIOGRAPHY OF SUGGESTED READING

Baselt, R.C. Disposition of Toxic Drugs and Chemicals in Man. Biomedical Publications, Davis, CA, 1982. Ellenhorn, M.J. and Barceloux, D. G Medical Toxicology. Elservier Science Publishing Company, Inc., New York, 1988

Gilman, A. G., and Goodman, L. S. The Pharmacological Fluids, in Martin WR(ed): Drug Addiction I, New York, Spring – Verlag, 1977.

Harvey, R.A., Champe, P.C. Lippincotts Illustrated Reviews. Pharmacology. 91-95, 1992.